Our	O
antibiotic	O
prediction	O
server	O
,	O
ABDpred	B-BT
,	O
used	O
a	O
soft	O
-	O
voting	O
technique	O
for	O
the	O
first	O
time	O
for	O
antibiotic	O
discovery	O
,	O
using	O
the	O
aggregation	O
of	O
top	O
four	O
classifiers	O
(	O
XGBoost	O
,	O
RF	O
,	O
GBC	O
and	O
DNN	O
).	O

As	O
MetaTiME	B-BT
MeCs	O
provides	O
a	O
highly	O
interpretable	O
basis	O
for	O
the	O
TME	O
in	O
single	O
cells	O
,	O
we	O
provided	O
a	O
toolkit	O
to	O
discover	O
MeC	O
signature	O
continuums	O
and	O
enriched	O
cell	O
states	O
in	O
scRNA	O
-	O
seq	O
TME	O
data	O
(	O
code	O
deposited	O
in	O
https	O
://	O
github	O
.	O
com	O
/	O
yi	O
-	O
zhang	O
/	O
MetaTiME	B-BT
).	O

The	O
same	O
simulations	O
can	O
be	O
performed	O
using	O
a	O
user	O
-	O
friendly	O
web	O
interface	O
,	O
WebMaBoSS	B-BT
[	O
35	O
]	O
available	O
at	O
this	O
address	O
:	O
https	O
://	O
maboss	O
.	O
curie	O
.	O
fr	O
/	O
webmaboss	B-BT
/).	O

Jalview	B-BT
a	O
free	O
cross	O
-	O
platform	O
program	O
for	O
multiple	O
sequence	O
alignment	O
editing	O
,	O
visualization	O
,	O
and	O
analysis	O
.	O

Reference	O
literature	O
was	O
used	O
to	O
find	O
marker	O
genes	O
to	O
manually	O
annotate	O
different	O
cell	O
clusters	O
,	O
with	O
the	O
assistance	O
of	O
the	O
Python	O
package	O
MetaTime	B-BT
(	O
Supplementary	O
Figures	O
S1G	O
,	O
H	O
;	O
Supplementary	O
Table	O
S2	O
).	O

tRigon	B-BT
session	O
report	O
in	O
html	O
-	O
format	O
for	O
a	O
k	O
-	O
means	O
clustering	O
analysis	O
including	O
all	O
inputs	O
,	O
setting	O
options	O
and	O
outputs	O
.	O
Additional	O
file	O
2	O
.	O

Additionally	O
,	O
in	O
the	O
multi	O
-	O
label	O
prediction	O
of	O
DM3Loc	O
and	O
MRSLpred	B-BT
models	O
,	O
only	O
the	O
five	O
subcellular	O
locations	O
(	O
cytosol	O
,	O
exosome	O
,	O
nucleus	O
,	O
ribosome	O
,	O
and	O
membrane	O
)	O
overlap	O
with	O
the	O
predicted	O
locations	O
of	O
DRpred	O
,	O
whereas	O
in	O
the	O
multi	O
-	O
label	O
predictor	O
proposed	O
by	O
Wang	O
et	O
al	O
.,	O
the	O
overlapping	O
subcellular	O
locations	O
with	O
DRpred	O
are	O
cytosol	O
,	O
exosome	O
,	O
nucleus	O
,	O
ribosome	O
,	O
and	O
cytoplasm	O
.	O

An	O
experimental	O
medical	O
device	O
,	O
the	O
Voyager	O
leverages	O
the	O
power	O
of	O
localized	O
,	O
ultra	O
-	O
low	O
(	O
0	O
-	O
22kHz	O
)	O
radio	O
frequency	O
energy	O
(	O
ulRFE	O
)	O
to	O
inhibit	O
cancers	O
including	O
GBM	O
(	O
Barkhoudarian	O
et	O
al	O
.	O

FRETpredict	B-BT
is	O
written	O
in	O
Python	O
and	O
is	O
available	O
as	O
a	O
Python	O
package	O
.	O

Additionally	O
,	O
DEGRONOPEDIA	B-BT
[	O
31	O
]	O
has	O
been	O
introduced	O
as	O
a	O
novel	O
web	O
server	O
dedicated	O
to	O
the	O
identification	O
and	O
analysis	O
of	O
degron	O
motifs	O
within	O
proteins	O
,	O
enabling	O
the	O
prediction	O
of	O
potential	O
N	O
-/	O
C	O
-	O
degrons	O
subsequent	O
to	O
proteolytic	O
events	O
(	O
summarized	O
in	O
Supplementary	O
Table	O
S1	O
).	O

In	O
addition	O
to	O
this	O
high	O
-	O
level	O
automation	O
of	O
analyses	O
,	O
PAPipe	B-BT
is	O
flexible	O
and	O
can	O
be	O
customized	O
by	O
users	O
.	O

As	O
a	O
proof	O
-	O
of	O
-	O
concept	O
,	O
we	O
used	O
MINNO	B-BT
to	O
conduct	O
an	O
empirical	O
refinement	O
of	O
three	O
metabolic	O
pathways	O
for	O
three	O
species	O
of	O
Borrelia	O
,	O
spirochetes	O
that	O
cause	O
Lyme	O
disease	O
and	O
relapsing	O
fever	O
in	O
humans	O
and	O
other	O
vertebrates	O
.	O
9	O
,	O
20Borrelia	O
spirochetes	O
follow	O
a	O
complex	O
life	O
cycle	O
in	O
which	O
they	O
are	O
sequentially	O
passed	O
from	O
ticks	O
to	O
a	O
mammalian	O
host	O
.	O
21	O
,	O
22	O
These	O
species	O
are	O
obligate	O
parasites	O
,	O
and	O
selective	O
pressure	O
has	O
streamlined	O
their	O
metabolic	O
networks	O
to	O
dispense	O
with	O
the	O
biosynthesis	O
of	O
many	O
metabolites	O
that	O
can	O
be	O
obtained	O
directly	O
from	O
their	O
host	O
.	O
19	O
,	O
20	O
Using	O
MINNO	B-BT
,	O
we	O
found	O
evidence	O
for	O
metabolic	O
streamlining	O
and	O
divergence	O
among	O
Lyme	O
disease	O
and	O
relapsing	O
fever	O
spirochetes	O
resulting	O
from	O
these	O
specific	O
host	O
/	O
vector	O
interactions	O
.	O

The	O
cross	O
-	O
sectional	O
size	O
of	O
the	O
prefabricated	O
set	O
of	O
arches	O
was	O
selected	O
as	O
a	O
0	O
.	O
2	O
m	O
×	O
2	O
m	O
cross	O
-	O
section	O
,	O
and	O
the	O
bolt	O
was	O
made	O
of	O
steel	O
.	O
Fig	O
.	O

During	O
quantitation	O
,	O
iMet	B-BT
-	I-BT
Q	I-BT
sequentially	O
detects	O
peaks	O
from	O
each	O
replicate	O
and	O
then	O
aligns	O
those	O
detected	O
peaks	O
across	O
replicates	O
/	O
samples	O
.	O

All	O
this	O
supports	O
the	O
assessment	O
that	O
MACS2	O
does	O
not	O
take	O
into	O
account	O
RD	O
-	O
scaling	O
and	O
overestimates	O
the	O
significance	O
of	O
cis	O
peaks	O
close	O
to	O
the	O
Malat1	O
gene	O
boundaries	O
,	O
which	O
is	O
corrected	O
by	O
the	O
BaRDIC	B-BT
algorithm	O
(	O
Figure	O
4D	O
).	O

subtilis	O
secretome	O
as	O
annotated	O
in	O
the	O
Subtiwiki	B-BT
knowledgebase	O
(	O
Supplementary	O
Fig	O
.	O

iPHoP	B-BT
differs	O
from	O
existing	O
HPTs	O
since	O
it	O
can	O
return	O
0	O
,	O
1	O
,	O
or	O
multiple	O
predicted	O
hosts	O
for	O
a	O
given	O
virus	O
.	O

At	O
4	O
months	O
of	O
age	O
,	O
aortic	O
arch	O
repair	O
was	O
performed	O
,	O
including	O
removal	O
of	O
the	O
ductus	O
arteriosus	O
and	O
remnant	O
left	O
aortic	O
arch	O
to	O
release	O
the	O
vascular	O
ring	O
.	O

In	O
this	O
manuscript	O
,	O
""""	O
KinCytE	B-BT
-	O
a	O
Kinase	O
to	O
Cytokine	O
Explorer	O
to	O
Identify	O
Molecular	O
Regulators	O
and	O
Potential	O
Therapeutic	O
""","	O
the	O
authors	O
present	O
a	O
web	O
resource	O
,	O
KinCytE	B-BT
,	O
that	O
lets	O
researchers	O
search	O
for	O
kinase	O
inhibitors	O
that	O
have	O
been	O
shown	O
to	O
affect	O
cytokine	O
and	O
chemokine	O
release	O
and	O
signaling	O
networks	O
.	O

Following	O
this	O
methodology	O
,	O
SyntenyViewer	B-BT
delivers	O
published	O
comparative	O
genomics	O
data	O
(	O
listed	O
in	O
Table	O
1	O
)	O
obtained	O
for	O
the	O
two	O
major	O
angiosperm	O
families	O
with	O
the	O
grasses	O
within	O
the	O
monocots	O
[	O
ancestral	O
grass	O
karyotype	O
(	O
AGK	O
)	O
with	O
12	O
protochromosomes	O
and	O
16	O
560	O
PGs	O
(	O
21	O
,	O
22	O
)]	O
and	O
the	O
eudicots	O
[	O
ancestral	O
eudicot	O
karyotype	O
(	O
AEK	O
)	O
with	O
21	O
chromosomes	O
and	O
10	O
286	O
PGs	O
(	O
23	O
)].	O

Another	O
non	O
-	O
microscopy	O
-	O
based	O
method	O
is	O
called	O
NanoDeep	O
(	O
Figure	O
10B	O
).	O

This	O
is	O
a	O
correction	O
to	O
:	O
Dmitry	O
E	O
Mylarshchikov	O
,	O
Arina	O
I	O
Nikolskaya	O
,	O
Olesja	O
D	O
Bogomaz	O
,	O
Anastasia	O
A	O
Zharikova	O
,	O
Andrey	O
A	O
Mironov	O
,	O
BaRDIC	B-BT
:	O
robust	O
peak	O
calling	O
for	O
RNA	O
–	O
DNA	O
interaction	O
data	O
,	O
NAR	O
Genomics	O
and	O
Bioinformatics	O
,	O
Volume	O
6	O
,	O
Issue	O
2	O
,	O
June	O
2024	O
,	O
lqae054	O
,	O
https	O
://	O
doi	O
.	O
org	O
/	O
10	O
.	O
1093	O
/	O
nargab	O
/	O
lqae054	O

reported	O
the	O
use	O
of	O
the	O
MatchMiner	B-BT
open	O
source	O
platform	O
to	O
computationally	O
match	O
genomically	O
profiled	O
cancer	O
patients	O
to	O
precision	O
medicine	O
clinical	O
trials	O
in	O
an	O
academic	O
large	O
-	O
volume	O
center	O
.	O

Using	O
ENDScript	B-BT
2	I-BT
.	I-BT
0	I-BT
(	O
Robert	O
and	O
Gouet	O
,	O
2014	O
),	O
residues	O
within	O
3	O
.	O
2	O
Å	O
and	O
3	O
.	O
2	O
-	O
5	O
Å	O
of	O
the	O
compound	O
were	O
evaluated	O
(	O
Figure	O
S5	O
).	O

Putative	O
nucleases	O
were	O
identified	O
by	O
searching	O
Subtiwiki	B-BT
functional	O
annotations	O
.	O

This	O
amount	O
is	O
more	O
than	O
double	O
the	O
estimated	O
cost	O
of	O
medicines	O
for	O
treatment	O
of	O
outpatient	O
pneumonia	O
in	O
Fiji	O
[	O
29	O
];	O
in	O
that	O
study	O
,	O
the	O
average	O
cost	O
of	O
medicines	O
ranged	O
from	O
$	O
1	O
.	O
3	O
for	O
Nausori	O
PHC	O
to	O
$	O
2	O
.	O
6	O
for	O
CWMH	O
(	O
in	O
2020	O
values	O
).	O

Sashimi	O
plots	O
were	O
generated	O
with	O
Sashimi	B-BT
.	I-BT
py	I-BT
.	O
74	O

Annotation	O
files	O
from	O
the	O
ATLAS	O
(	O
3	O
)	O
and	O
MetaPathways	B-BT
(	O
18	O
,	O
19	O
)	O
pipelines	O
described	O
above	O
are	O
available	O
at	O
https	O
://	O
doi	O
.	O
org	O
/	O
10	O
.	O
6084	O
/	O
m9	O
.	O
figshare	O
.	O
21126166	O
.	O

a	O
Illustration	O
of	O
a	O
typical	O
pyHiM	B-BT
analysis	O
on	O
mouse	O
tissues	O
:	O
examples	O
of	O
raw	O
data	O
are	O
shown	O
in	O
the	O
top	O
row	O
and	O
the	O
most	O
relevant	O
pyHiM	B-BT
outputs	O
are	O
shown	O
in	O
the	O
bottom	O
row	O
.	O

(%)	O
Constipation28	O
(	O
56	O
)	O
0Altered	O
liver	O
enzymes21	O
(	O
43	O
)	O
2	O
(	O
4	O
)	O
Renal	O
insufficiency13	O
(	O
27	O
)	O
1	O
(	O
2	O
)	O
Anaemia11	O
(	O
22	O
)	O
0Fatigue11	O
(	O
22	O
)	O
0Nausea	O
/	O
vomiting8	O
(	O
16	O
)	O
2	O
(	O
4	O
)	O
Leukopenia2	O
(	O
4	O
)	O
1	O
(	O
2	O
)	O
Thrombocytopenia2	O
(	O
4	O
)	O
0Table	O
5Renal	O
function	O
(	O
GFRa	O
,	O
MDRDb	O
formula	O
)	O
before	O
and	O
after	O
STZ	O
CTxStart	O
STZ	O
CTx	O
n	O
(%)	O
cStop	O
STZ	O
CTx	O
n	O
(%)	O
c6	O
months	O
after	O
the	O
end	O
of	O
STZ	O
CTx	O
n	O
(%)	O
d12	O
months	O
after	O
the	O
end	O
of	O
STZ	O
CTx	O
n	O
(%)	O
e	O
>	O
60	O
ml	O
/	O
min41	O
(	O
85	O
)	O
35	O
(	O
73	O
)	O
20	O
(	O
57	O
)	O
14	O
(	O
52	O
)	O
60	O
–	O
30	O
ml	O
/	O
min7	O
(	O
15	O
)	O
12	O
(	O
25	O
)	O
14	O
(	O
40	O
)	O
11	O
(	O
41	O
)	O
29	O
–	O
15	O
ml	O
/	O
min0	O
(	O
0	O
)	O
1	O
(	O
2	O
)	O
1	O
(	O
3	O
)	O
2	O
(	O
7	O
)<	O
15	O
ml	O
/	O
min0000aGFR	O
glomerular	O
filtration	O
rate	O
.	O
bMDRD	O
Modification	O
of	O
Diet	O
in	O
Renal	O
Disease	O
.	O
cGFR	O
available	O
in	O
48	O
patients	O
.	O
dGFR	O
available	O
in	O
35	O
patients	O
.	O
eGFR	O
available	O
in	O
27	O
patients	O
.	O

The	O
combination	O
of	O
AI	O
with	O
spatial	O
transcription	O
and	O
single	O
-	O
cell	O
sequencing	O
has	O
been	O
carried	O
out	O
,	O
as	O
in	O
the	O
novel	O
self	O
-	O
supervised	O
deep	O
learning	O
framework	O
called	O
BIDCell	B-BT
[	O
93	O
],	O
which	O
combines	O
single	O
-	O
cell	O
transcriptome	O
data	O
and	O
cellular	O
morphology	O
information	O
,	O
which	O
not	O
only	O
provides	O
good	O
segmentation	O
of	O
cells	O
,	O
but	O
also	O
learns	O
to	O
spatially	O
discriminate	O
between	O
gene	O
expression	O
and	O
cellular	O
morphology	O
,	O
providing	O
a	O
direction	O
for	O
multidimensional	O
characterization	O
of	O
TME	O
.	O

In	O
general	O
these	O
methods	O
are	O
characterised	O
by	O
a	O
“	O
repeat	O
first	O
”	O
approach	O
,	O
in	O
that	O
they	O
first	O
look	O
for	O
dispersed	O
repetitive	O
sequences	O
or	O
structural	O
motifs	O
and	O
then	O
try	O
to	O
cluster	O
them	O
and	O
extend	O
them	O
to	O
recreate	O
finally	O
the	O
complete	O
sequence	O
of	O
the	O
original	O
TE	O
.	O

In	O
this	O
section	O
,	O
we	O
employed	O
PermuteDDS	B-BT
to	O
predict	O
novel	O
synergistic	O
drug	O
combinations	O
that	O
had	O
not	O
been	O
previously	O
tested	O
.	O

The	O
Supreme	O
Court	O
’	O
s	O
ruling	O
further	O
perpetuates	O
and	O
extends	O
the	O
marginalisation	O
of	O
LGBTQ	O
+	O
couples	O
from	O
social	O
structures	O
crucial	O
to	O
their	O
health	O
and	O
well	O
-	O
being	O
.	O

3A	O
),	O
compared	O
with	O
the	O
time	O
per	O
stitch	O
for	O
the	O
first	O
three	O
cases	O
.	O

PyChelator	B-BT
Colab	O
is	O
also	O
modified	O
to	O
use	O
the	O
built	O
-	O
in	O
Python	O
Decimal	O
module	O
,	O
introducing	O
user	O
-	O
defined	O
precision	O
in	O
the	O
calculations	O
,	O
which	O
are	O
otherwise	O
limited	O
by	O
double	O
precision	O
in	O
the	O
floating	O
-	O
point	O
arithmetic	O
of	O
Python	O
and	O
JavaScript	O
.	O

Furthermore	O
,	O
HTSlib	B-BT
has	O
demonstrated	O
the	O
best	O
performance	O
among	O
many	O
competitors	O
(	O
Bonfield	O
et	O
al	O
.	O

In	O
summary	O
,	O
Sven	O
Ivar	O
Seldinger	O
'	O
s	O
introduction	O
of	O
a	O
less	O
invasive	O
method	O
for	O
vascular	O
access	O
has	O
not	O
only	O
enhanced	O
the	O
capability	O
of	O
medical	O
practitioners	O
to	O
perform	O
a	O
wide	O
range	O
of	O
procedures	O
safely	O
but	O
has	O
also	O
greatly	O
reduced	O
patient	O
risk	O
and	O
discomfort	O
.	O

LTR_FINDER	O
v1	O
.	O
0520	O
and	O
RepeatScout	O
v1	O
.	O
0521	O
were	O
primarily	O
used	O
to	O
build	O
a	O
de	O
novo	O
repeat	O
sequences	O
library	O
of	O
Sijihua	O
genome	O
,	O
which	O
was	O
classified	O
by	O
using	O
PASTEClassifier	B-BT
v1	O
.	O
022	O
and	O
merged	O
with	O
Repbase	O
v19	O
.	O
0623	O
database	O
as	O
the	O
final	O
repeat	O
sequences	O
database	O
.	O

Users	O
can	O
choose	O
between	O
processing	O
human	O
or	O
animal	O
experiment	O
data	O
with	O
calculations	O
on	O
specimen	O
or	O
single	O
-	O
structure	O
levelLoading	O
datatRigon	B-BT
can	O
also	O
be	O
used	O
to	O
load	O
other	O
data	O
(	O
e	O
.	O
g	O
.,	O
other	O
omics	O
datasets	O
)	O
or	O
already	O
processed	O
pathomics	O
filesStatisticsDescriptive	O
statisticsBased	O
on	O
a	O
provided	O
group	O
label	O
tRigon	B-BT
can	O
calculate	O
summary	O
statistics	O
(	O
e	O
.	O
g	O
.,	O
mean	O
,	O
median	O
,	O
standard	O
deviation	O
,	O
interquartile	O
range	O
)	O
for	O
each	O
chosen	O
featureStatistical	O
teststRigon	B-BT
supports	O
a	O
range	O
of	O
simple	O
non	O
-	O
parametric	O
statistical	O
tests	O
such	O
as	O
:(	O
1	O
)	O
pairwise	O
Wilcoxon	O
-	O
rank	O
tests	O
with	O
Bonferroni	O
correction	O
for	O
multiple	O
testing	O
(	O
2	O
)	O
Kruskal	O
–	O
Wallis	O
tests	O
(	O
3	O
)	O
differences	O
in	O
median	O
with	O
bootstrapped	O
confidence	O
intervals	O
for	O
each	O
desired	O
feature	O
and	O
provided	O
group	O
labelCorrelationSimple	O
and	O
multiple	O
correlations	O
based	O
on	O
the	O
Pearson	O
-	O
correlation	O
coefficient	O
can	O
be	O
calculated	O
and	O
visualized	O
as	O
a	O
scatter	O
plot	O
or	O
correlation	O
matrix	O
for	O
each	O
chosen	O
feature	O
.	O

SLiM	O
-	O
CRAB	O
-	O
positive	O
patients	O
presented	O
with	O
either	O
two	O
(	O
20	O
/	O
30	O
,	O
67	O
%),	O
three	O
(	O
7	O
/	O
30	O
,	O
23	O
%),	O
or	O
four	O
(	O
3	O
/	O
30	O
,	O
10	O
%)	O
features	O
.	O

Software	O
like	O
MSiReader	O
v2	O
.	O
0	O
or	O
RmsiGUI	B-BT
(	O
R	O
package	O
)	O
allows	O
for	O
the	O
overlay	O
of	O
optical	O
and	O
ion	O
images	O
[	O
83	O
,	O
87	O
].	O

Comparison	O
of	O
multi	O
-	O
label	O
prediction	O
performance	O
with	O
DM3Loc	O
,	O
MRSLpred	B-BT
,	O
and	O
Clarion	O
predictors	O
at	O
five	O
subcellular	O
localizations	O
on	O
the	O
independent	O
test	O
set	O
(	O
membrane	O
,	O
cytosol	O
,	O
exosome	O
,	O
nucleus	O
,	O
ribosome	O
).	O

To	O
assign	O
short	O
non	O
-	O
coding	O
RNAs	O
to	O
tRNAs	O
,	O
alignment	O
files	O
for	O
18	O
–	O
36	O
nucleotide	O
small	O
RNAs	O
generated	O
by	O
tinyRNA	B-BT
(	O
above	O
)	O
were	O
converted	O
to	O
bed	O
files	O
using	O
bedtools	O
and	O
then	O
intersected	O
with	O
the	O
tRNA	O
coordinates	O
using	O
bedtools	O
intersect	O
.	O

By	O
learning	O
and	O
testing	O
the	O
m6A	O
datasets	O
identified	O
from	O
23	O
human	O
tissues	O
,	O
the	O
newly	O
integrated	O
framework	O
m6A	B-BT
-	I-BT
TCPred	I-BT
(	O
see	O
Fig	O
.	O

This	O
function	O
is	O
utilized	O
to	O
generate	O
comprehensive	O
predictions	O
in	O
scAnnoX	B-BT
,	O
and	O
a	O
subsequent	O
validation	O
conducted	O
across	O
various	O
datasets	O
demonstrated	O
the	O
commendable	O
robustness	O
of	O
the	O
performance	O
achieved	O
by	O
scAnnoX	B-BT
.	O

Vincent	O
(	O
18	O
)	O
-	O
Osama	O
Zaidat	O
(	O
PI	O
),	O
Eugene	O
Lin	O
(	O
Sub	O
-	O
I	O
),	O
Tina	O
M	O
Steinhauser	O
(	O
CRC	O
),	O
Dee	O
Tilley	O
(	O
CRC	O
),	O
Julie	O
Goins	O
-	O
Whitmore	O
(	O
past	O
CRC	O
),	O
Brandi	O
Breseman	O
(	O
past	O
CRC	O
),	O
Melissa	O
A	O
Thomas	O
(	O
past	O
CRC	O
);	O
University	O
of	O
Pittsburgh	O
(	O
17	O
)	O
-	O
Ashutosh	O
Jadhav	O
(	O
PI	O
and	O
past	O
Sub	O
-	O
I	O
),	O
Bradley	O
Gross	O
(	O
Sub	O
-	O
I	O
),	O
Lisa	O
Baxendell	O
(	O
CRC	O
),	O
Patricia	O
Feineigle	O
(	O
CRC	O
),	O
Vicki	O
Gilchrist	O
(	O
CRC	O
),	O
Brian	O
Jankowitz	O
(	O
past	O
Sub	O
-	O
I	O
and	O
past	O
PI	O
),	O
Andrew	O
Ducruet	O
(	O
past	O
Sub	O
-	O
I	O
),	O
David	O
Panczkowski	O
(	O
past	O
Sub	O
-	O
I	O
),	O
Hazem	O
Shoirah	O
(	O
past	O
Sub	O
-	O
I	O
),	O
Alhamza	O
Al	O
-	O
Bayati	O
(	O
past	O
Sub	O
-	O
I	O
),	O
Amin	O
Aghaebrahim	O
(	O
past	O
Sub	O
-	O
I	O
),	O
Tudor	O
Jovin	O
(	O
past	O
Sub	O
-	O
I	O
),	O
Greg	O
Weiner	O
(	O
past	O
Sub	O
-	O
I	O
),	O
Cynthia	O
Kenmuir	O
(	O
past	O
Sub	O
-	O
I	O
),	O
Prasanna	O
Tadi	O
(	O
past	O
Sub	O
-	O
I	O
),	O
Gregory	O
Walker	O
(	O
past	O
Sub	O
-	O
I	O
),	O
Kelsea	O
Haibach	O
(	O
past	O
CRC	O
),	O
Carlynn	O
Graves	O
(	O
past	O
CRC	O
),	O
Yvonne	O
Cannon	O
(	O
past	O
CRC	O
);	O
WellStar	O
Research	O
Institute	O
(	O
16	O
)	O
-	O
Ahmad	O
Khaldi	O
(	O
PI	O
),	O
Rishi	O
Gupta	O
(	O
Sub	O
-	O
I	O
),	O
Marianne	O
Bain	O
(	O
CRC	O
),	O
Laura	O
Murphy	O
(	O
CRC	O
),	O
Andrew	O
K	O
Johnson	O
(	O
past	O
Sub	O
-	O
I	O
),	O
Barbara	O
A	O
Foster	O
(	O
past	O
CRC	O
),	O
Tasha	O
Futch	O
(	O
past	O
CRC	O
),	O
Portia	O
Thomas	O
(	O
past	O
CRC	O
);	O
RIA	O
/	O
Swedish	O
(	O
14	O
)	O
-	O
Don	O
Frei	O
(	O
current	O
PI	O
and	O
past	O
Sub	O
-	O
I	O
),	O
Richard	O
Bellon	O
(	O
Sub	O
-	O
I	O
),	O
Benjamin	O
Atchie	O
(	O
Sub	O
-	O
I	O
),	O
Ian	O
Kaminsky	O
(	O
Sub	O
-	O
I	O
),	O
Lisa	O
Kodis	O
(	O
CRC	O
),	O
Mark	O
Talley	O
(	O
CRC	O
),	O
Tiffany	O
Talley	O
(	O
CRC	O
),	O
Alex	O
Edinger	O
(	O
CRC	O
),	O
David	O
Loy	O
(	O
past	O
PI	O
and	O
Sub	O
-	O
I	O
),	O
Dan	O
Huddle	O
(	O
past	O
Sub	O
-	O
I	O
),	O
Michelle	O
Lexin	O
(	O
past	O
CRC	O
),	O
Brad	O
Fasbinder	O
(	O
CRC	O
),	O
Alicia	O
Drew	O
(	O
past	O
CRC	O
),	O
Joanna	O
Snead	O
(	O
past	O
CRC	O
),	O
Ashley	O
Bitner	O
(	O
past	O
CRC	O
),	O
Sarah	O
Weiss	O
(	O
past	O
CRC	O
),	O
Nouara	O
Sadaoui	O
(	O
past	O
CRC	O
);	O
Tufts	O
Medical	O
Center	O
(	O
12	O
)	O
-	O
Adel	O
Malek	O
(	O
PI	O
),	O
Emma	O
Jost	O
-	O
Price	O
(	O
CRC	O
),	O
Keri	O
Sullivan	O
(	O
CRC	O
),	O
Haley	O
Huggins	O
(	O
past	O
CRC	O
),	O
Lindsey	O
Soll	O
(	O
past	O
CRC	O
),	O
Sarah	O
Gans	O
(	O
past	O
CRC	O
),	O
Michelle	O
Bettle	O
(	O
past	O
CRC	O
);	O
Cleveland	O
Clinic	O
Foundation	O
(	O
10	O
)	O
-	O
Gabor	O
Toth	O
(	O
PI	O
),	O
Mark	O
Bain	O
(	O
Sub	O
-	O
I	O
),	O
Peter	O
Rasmussen	O
(	O
Sub	O
-	O
I	O
),	O
M	O
Shazam	O
Hussain	O
(	O
Sub	O
-	O
I	O
),	O
Nina	O
Moore	O
(	O
Sub	O
-	O
I	O
),	O
Thomas	O
Masaryk	O
(	O
Sub	O
-	O
I	O
),	O
Mohamed	O
Elgabaly	O
(	O
Sub	O
-	O
I	O
),	O
Erin	O
Bynum	O
(	O
CRC	O
),	O
Russell	O
Cerejo	O
(	O
past	O
Sub	O
-	O
I	O
),	O
Julian	O
Hardman	O
(	O
past	O
Sub	O
-	O
I	O
),	O
Seby	O
John	O
(	O
past	O
Sub	O
-	O
I	O
),	O
Andrew	O
Bauer	O
(	O
past	O
Sub	O
-	O
I	O
),	O
Erin	O
Mayock	O
(	O
past	O
CRC	O
),	O
Vikram	O
Puvenna	O
(	O
past	O
CRC	O
),	O
Jenny	O
Peih	O
-	O
Chir	O
Tsai	O
(	O
past	O
Sub	O
-	O
I	O
);	O
SUNY	O
Buffalo	O
(	O
9	O
)	O
-	O
Adnan	O
Siddiqui	O
(	O
PI	O
),	O
Elad	O
Levy	O
(	O
Sub	O
-	O
I	O
),	O
Kenneth	O
Snyder	O
(	O
Sub	O
-	O
I	O
),	O
Jason	O
Davies	O
(	O
Sub	O
-	O
I	O
),	O
Mary	O
Hartney	O
(	O
CRC	O
),	O
Jonna	O
Sakowski	O
(	O
CRC	O
),	O
Courtney	O
Drozdowski	O
(	O
past	O
CRC	O
),	O
Heather	O
Ross	O
(	O
past	O
CRC	O
),	O
Linda	O
Bookhagen	O
(	O
past	O
CRC	O
);	O
Beth	O
Israel	O
Deaconess	O
(	O
7	O
)	O
-	O
Ajith	O
Thomas	O
(	O
PI	O
),	O
Christopher	O
Ogilvy	O
(	O
Sub	O
-	O
I	O
),	O
Patricia	O
Baum	O
(	O
CRC	O
);	O
Virginia	O
Commonwealth	O
(	O
7	O
)	O
-	O
John	O
Reavey	O
-	O
Cantwell	O
(	O
PI	O
),	O
Dennis	O
Rivet	O
(	O
Co	O
-	O
PI	O
),	O
Charlotte	O
Gilman	O
(	O
CRC	O
);	O
Cedars	O
Sinai	O
Medical	O
Center	O
(	O
6	O
)	O
-	O
Michael	O
Alexander	O
(	O
PI	O
),	O
Franklin	O
Moser	O
(	O
Sub	O
-	O
I	O
),	O
Marcel	O
Maya	O
(	O
Sub	O
-	O
I	O
),	O
Michael	O
Schiraldi	O
(	O
Sub	O
-	O
I	O
),	O
Vicki	O
Manoukian	O
,	O
MA	O
(	O
CRC	O
),	O
Paula	O
Eboli	O
(	O
past	O
Sub	O
-	O
I	O
);	O
Johns	O
Hopkins	O
University	O
(	O
6	O
)	O
-	O
Justin	O
Caplan	O
(	O
current	O
PI	O
),	O
Bowen	O
Jiang	O
(	O
Sub	O
-	O
I	O
),	O
Matthew	O
Bender	O
(	O
Sub	O
-	O
I	O
),	O
Ellen	O
Sheehan	O
(	O
CRC	O
),	O
Jessica	O
Wollett	O
(	O
CRC	O
),	O
Geoffrey	O
Colby	O
(	O
past	O
PI	O
),	O
Lauren	O
Dise	O
(	O
past	O
CRC	O
),	O
Anna	O
Bugaeva	O
(	O
past	O
CRC	O
),	O
Barbara	O
Michniewicz	O
(	O
past	O
CRC	O
),	O
Thomas	O
Hemmingson	O
(	O
past	O
CRC	O
);	O
Christiana	O
Care	O
Health	O
Services	O
(	O
5	O
)	O
-	O
Sudhakar	O
Satti	O
(	O
PI	O
),	O
Thinesh	O
Sivapatham	O
(	O
Sub	O
-	O
I	O
),	O
Robie	O
Zent	O
(	O
CRC	O
),	O
Ann	O
Marie	O
Le	O
Noir	O
(	O
CRC	O
);	O
Hospital	O
of	O
the	O
University	O
of	O
PA	O
(	O
5	O
)	O
-	O
David	O
Kung	O
(	O
current	O
PI	O
and	O
past	O
Sub	O
-	O
I	O
),	O
Bryan	O
Pukenas	O
(	O
Sub	O
-	O
I	O
),	O
Robert	O
Hurst	O
(	O
Sub	O
-	O
I	O
),	O
Timothy	O
Prior	O
(	O
CRC	O
),	O
Whitney	O
Sarchiapone	O
(	O
CRC	O
),	O
Yelena	O
Gorelik	O
(	O
past	O
CRC	O
),	O
Francis	O
Quattrone	O
(	O
past	O
CRC	O
),	O
Michelle	O
J	O
.	O

The	O
normalized	O
and	O
imputed	O
data	O
generated	O
by	O
FlexStat	B-BT
are	O
available	O
as	O
downloadable	O
files	O
for	O
downstream	O
analysis	O
.	O

Ivar	O
Rønnestad	O
:	O
Conceptualization	O
,	O
Methodology	O
,	O
Investigation	O
,	O
Writing	O
–	O
review	O
&	O
editing	O
.	O

WebMaBoSS	B-BT
can	O
also	O
perform	O
sensitivity	O
analyses	O
to	O
check	O
the	O
effect	O
of	O
a	O
knock	O
-	O
in	O
/	O
knock	O
-	O
out	O
of	O
each	O
node	O
on	O
the	O
network	O
.	O

REAGENT	O
or	O
RESOURCESOURCEIDENTIFIERAntibodiesAnti	O
-	O
γH2AX	O
Ser139Cell	O
signaling	O
TechnologyCat	O
#	O
9718	O
,	O
RRID	O
:	O
AB_2118009Anti	O
-	O
H2AXCell	O
signaling	O
TechnologyCat	O
#	O
2595	O
,	O
RRID	O
:	O
AB_10694556Anti	O
-	O
p21Cell	O
signaling	O
TechnologyCat	O
#	O
2947	O
,	O
RRID	O
:	O
AB_823586Anti	O
-	O
CDC2Cell	O
signaling	O
TechnologyCat	O
#	O
9116	O
,	O
RRID	O
:	O
AB_2074795Anti	O
-	O
CDC25cCell	O
signaling	O
TechnologyCat	O
#	O
4688	O
,	O
RRID	O
:	O
AB_560956Anti	O
-	O
cyclin	O
B1Cell	O
signaling	O
TechnologyCat	O
#	O
12231	O
,	O
RRID	O
:	O
AB_2783553Anti	O
-	O
c	O
-	O
MycCell	O
signaling	O
TechnologyCat	O
#	O
9402	O
,	O
RRID	O
:	O
AB_2151827Anti	O
-	O
BidCell	O
signaling	O
TechnologyCat	O
#	O
2002	O
,	O
RRID	O
:	O
AB_10692485Anti	O
-	O
ATMCell	O
signaling	O
TechnologyCat	O
#	O
2873	O
,	O
RRID	O
:	O
AB_2062659Anti	O
-	O
p	O
-	O
ATM	O
Ser1981Cell	O
signaling	O
TechnologyCat	O
#	O
5883	O
,	O
RRID	O
:	O
AB_10835213Anti	O
-	O
ATRCell	O
signaling	O
TechnologyCat	O
#	O
2790	O
,	O
RRID	O
:	O
AB_2227860Anti	O
-	O
p	O
-	O
ATRCell	O
signaling	O
TechnologyCat	O
#	O
2853	O
,	O
RRID	O
:	O
AB_2290281Anti	O
-	O
Chk1Cell	O
signaling	O
TechnologyCat	O
#	O
2360	O
,	O
RRID	O
:	O
AB_2080320Anti	O
-	O
p	O
-	O
Chk1	O
Ser348Cell	O
signaling	O
TechnologyCat	O
#	O
2348	O
,	O
RRID	O
:	O
AB_331212Anti	O
-	O
Chk2Cell	O
signaling	O
TechnologyCat	O
#	O
6334	O
,	O
RRID	O
:	O
AB_11178526Anti	O
-	O
p	O
-	O
Chk2	O
Thr68Cell	O
signaling	O
TechnologyCat	O
#	O
2661	O
,	O
RRID	O
:	O
AB_331479Anti	O
-	O
caspase	O
9Cell	O
signaling	O
TechnologyCat	O
#	O
9508	O
,	O
RRID	O
:	O
AB_2068620Anti	O
-	O
caspase	O
8Cell	O
signaling	O
TechnologyCat	O
#	O
9746	O
,	O
RRID	O
:	O
AB_2275120Anti	O
-	O
p	O
-	O
Rb	O
(	O
Ser807	O
/	O
811	O
)	O
Cell	O
signaling	O
TechnologyCat	O
#	O
8516	O
,	O
RRID	O
:	O
AB_11178658Anti	O
-	O
p53Cell	O
signaling	O
TechnologyCat	O
#	O
2524	O
,	O
RRID	O
:	O
AB_331743Anti	O
-	O
cyclin	O
ASanta	O
Cruz	O
BiotechnologyCat	O
#	O
sc	O
-	O
751	O
,	O
RRID	O
:	O
AB_631329Anti	O
-	O
cyclin	O
ESanta	O
Cruz	O
BiotechnologyCat	O
#	O
sc	O
-	O
247	O
,	O
RRID	O
:	O
AB_627357Anti	O
-	O
cyclin	O
D1Santa	O
Cruz	O
BiotechnologyCat	O
#	O
sc	O
-	O
753	O
,	O
RRID	O
:	O
AB_2070433Anti	O
-	O
CDK2Cell	O
signaling	O
TechnologyCat	O
#	O
2546	O
,	O
RRID	O
:	O
AB_2276129Anti	O
-	O
RbSanta	O
Cruz	O
BiotechnologyCat	O
#	O
sc	O
-	O
50	O
,	O
RRID	O
:	O
AB_632339Anti	O
-	O
p	O
-	O
Rb	O
(	O
Ser249	O
)	O
Santa	O
Cruz	O
BiotechnologyCat	O
#	O
sc	O
-	O
16671	O
,	O
RRID	O
:	O
AB_655229Anti	O
-	O
β	O
-	O
actinSigma	O
-	O
AldrichCat	O
#	O
A5441	O
,	O
RRID	O
:	O
AB_476744Anti	O
-	O
Mouse	O
IgG	O
,	O
HRP	O
-	O
linkedCell	O
signaling	O
TechnologyCat	O
#	O
7076	O
,	O
RRID	O
:	O
AB_330924Anti	O
-	O
Rabbit	O
IgG	O
,	O
HRP	O
-	O
linkedCell	O
signaling	O
TechnologyCat	O
#	O
7074	O
,	O
RRID	O
:	O
AB_2099233Chemicals	O
,	O
peptides	O
,	O
and	O
recombinant	O
proteinsDMSOSigma	O
-	O
AldrichCat	O
#	O
8418DoxorubicinSigma	O
-	O
AldrichCat	O
#	O
D1515Protease	O
/	O
phosphatase	O
inhibitors	O
cocktailSigma	O
-	O
AldrichCat	O
#	O
MSSAFEEnhanced	O
Chemiluminescence	O
reagentBioradCat	O
#	O
1705061SYBR	O
goldInvitrogenCat	O
#	O
S11494Critical	O
commercial	O
assaysRNA	O
extraction	O
kitNorgen	O
BiotekCat	O
#	O
17200Comet	O
assay	O
kitTrevigenCat	O
#	O
4250	O
-	O
050	O
-	O
KSuperScript	O
VILO	O
cDNA	O
Synthesis	O
kitInvitrogenCat	O
#	O
11754050Ion	O
Library	O
TaqMan	O
™	O
Quantitation	O
KitApplied	O
BiosystemsCat	O
#	O
4468802GoTaq	O
qPCR	O
master	O
mixPromegaCat	O
#	O
A6001FITC	O
Annexin	O
V	O
Apoptosis	O
Detection	O
KitBecton	O
DickensonCat	O
#	O
556547Experimental	O
models	O
:	O
Cell	O
linesMCF7University	O
Medical	O
Center	O
Hamburg	O
-	O
EppendorfN	O
/	O
AMDA	O
-	O
MB	O
-	O
231University	O
Medical	O
Center	O
Hamburg	O
-	O
EppendorfN	O
/	O
AA549University	O
Medical	O
Center	O
Hamburg	O
-	O
EppendorfN	O
/	O
AHCT116University	O
Medical	O
Center	O
Hamburg	O
-	O
EppendorfN	O
/	O
AHepG2University	O
Medical	O
Center	O
Hamburg	O
-	O
EppendorfN	O
/	O
AU87University	O
Medical	O
Center	O
Hamburg	O
-	O
EppendorfN	O
/	O
AU373University	O
Medical	O
Center	O
Hamburg	O
-	O
EppendorfN	O
/	O
AHeLaUniversity	O
Medical	O
Center	O
Hamburg	O
-	O
EppendorfN	O
/	O
AF180University	O
Medical	O
Center	O
Hamburg	O
-	O
EppendorfN	O
/	O
AHME1ATCCCat	O
#	O
CRL	O
-	O
4010HCT116	O
CDK4	O
KOUniversity	O
of	O
SharjahN	O
/	O
ASoftware	O
and	O
algorithmsGraphPad	O
Prism6GraphPadhttps	O
://	O
www	O
.	O
graphpad	O
.	O
com	O
/	O
scientificsoftware	O
/	O
prism	O
/	O
ImageJImageJhttps	O
://	O
imagej	O
.	O
nih	O
.	O
gov	O
/	O
ij	O
/	O
Image	O
LabBioradhttps	O
://	O
www	O
.	O
bio	O
-	O
rad	O
.	O
com	O
/	O
en	O
-	O
ae	O
/	O
product	O
/	O
image	O
-	O
lab	O
-	O
software	O
?	O
ID	O
=	O
KRE6P5E8ZRotor	O
-	O
gene	O
QQiagenhttps	O
://	O
www	O
.	O
qiagen	O
.	O
com	O
/	O
kr	O
/	O
resources	O
/	O
resourcedetail	O
?	O
id	O
=	O
8435805b	O
-	O
2c5d	O
-	O
4fa9	O
-	O
948c	O
-	O
a43de75a7ee1	O
&	O
lang	O
=	O
enFlow	O
JoTree	O
Starhttps	O
://	O
www	O
.	O
flowjo	O
.	O
com	O
/	O
Ion	O
Torrent	O
Software	O
SuiteThermo	O
Fisher	O
Scientifichttps	O
://	O
www	O
.	O
thermofisher	O
.	O
com	O
/	O
ae	O
/	O
en	O
/	O
home	O
/	O
life	O
-	O
science	O
/	O
sequencing	O
/	O
next	O
-	O
generation	O
-	O
sequencing	O
/	O
ion	O
-	O
torrent	O
-	O
next	O
-	O
generation	O
-	O
sequencing	O
-	O
workflow	O
/	O
ion	O
-	O
torrent	O
-	O
next	O
-	O
generation	O
-	O
sequencing	O
-	O
data	O
-	O
analysis	O
-	O
workflow	O
/	O
ion	O
-	O
torrent	O
-	O
suite	O
-	O
software	O
.	O
htmlMSD	O
Enhanced	O
ChemstationShimadzuhttps	O
://	O
www	O
.	O
shimadzu	O
.	O
com	O
/	O
an	O
/	O
products	O
/	O
gas	O
-	O
chromatograph	O
-	O
mass	O
-	O
spectrometry	O
/	O
gc	O
-	O
ms	O
-	O
software	O
/	O
index	O
.	O
html	O

We	O
identified	O
each	O
pair	O
as	O
a	O
(	O
n	O
)	O
initial	O
/	O
raw	O
Domain2GO	B-BT
mapping	O
.	O

Corresponding	O
author	O
:	O
Yu	O
-	O
Jie	O
Shu	O
,	O
MD	O
,	O
Doctor	O
,	O
Department	O
of	O
Gastroenterology	O
,	O
Yinzhou	O
District	O
Second	O
Hospital	O
,	O
No	O
.	O

MAG	O
is	O
also	O
available	O
in	O
US	O
DOE	O
Joint	O
Genome	O
Institute	O
’	O
s	O
Integrated	B-BT
Microbial	I-BT
Genomes	I-BT
(	I-BT
IMG	I-BT
)	I-BT
system	O
under	O
the	O
taxon	O
ID	O
2886190707	O
.	O

Greta	O
Bellinzona	O
(	O
Conceptualization	O
[	O
equal	O
],	O
Data	O
curation	O
[	O
lead	O
],	O
Formal	O
analysis	O
[	O
lead	O
],	O
Investigation	O
[	O
lead	O
],	O
Methodology	O
[	O
lead	O
],	O
Writing	O
—	O
original	O
draft	O
[	O
lead	O
]),	O
Davide	O
Sassera	O
(	O
Conceptualization	O
[	O
equal	O
],	O
Funding	O
acquisition	O
[	O
lead	O
],	O
Supervision	O
[	O
supporting	O
],	O
Writing	O
—	O
review	O
&	O
editing	O
[	O
supporting	O
]),	O
and	O
Alexandre	O
M	O
.	O
J	O
.	O
J	O
.	O

The	O
cooltools	B-BT
used	O
for	O
the	O
computation	O
of	O
insulation	O
score	O
is	O
available	O
at	O
https	O
://	O
github	O
.	O
com	O
/	O
open2c	O
/	O
cooltools	B-BT
.	O

HTSLIB	B-BT
(	O
Bonfield	O
et	O
al	O
.	O

In	O
this	O
regard	O
,	O
the	O
Supreme	O
Constitutional	O
Court	O
also	O
ruled	O
“	O
the	O
unconstitutionality	O
of	O
the	O
text	O
of	O
Article	O
23	O
of	O
the	O
Customs	O
Law	O
issued	O
by	O
Presidential	O
Decree	O
No	O
.	O

pyHiM	B-BT
employs	O
a	O
modular	O
architecture	O
,	O
allowing	O
independent	O
execution	O
of	O
analysis	O
steps	O
and	O
customization	O
according	O
to	O
sample	O
specificity	O
and	O
computing	O
resources	O
.	O

Egor	O
Guguchkin	O
,	O
Artem	O
Kasianov	O
,	O
Maksim	O
Belenikin	O
,	O
Gaukhar	O
Zobkova	O
,	O
Ekaterina	O
Kosova	O
,	O
Vsevolod	O
Makeev	O
and	O
Evgeny	O
Karpulevich	O

2scPrisma	B-BT
manipulates	O
the	O
cell	O
cycle	O
signal	O
in	O
HeLa	O
cells	O
.	O
a	O
,	O
PCA	O
representation	O
of	O
683	O
cells	O
in	O
the	O
unordered	O
and	O
ordered	O
raw	O
gene	O
expression	O
data	O
,	O
and	O
data	O
following	O
spectral	O
cyclic	O
enhancement	O
and	O
filtering	O
.	O

We	O
then	O
transduced	O
these	O
cells	O
with	O
lentiviruses	O
with	O
PCP	O
-	O
sfGFP	O
—	O
the	O
original	O
protein	O
of	O
the	O
CRISPR	O
-	O
Sirius	O
system	O
[	O
22	O
]—	O
and	O
selected	O
cells	O
expressing	O
PCP	O
-	O
sfGFP	O
by	O
FACS	O
.	O

Our	O
study	O
found	O
that	O
AuraGain	O
and	O
Supreme	O
exhibited	O
superior	O
GT	O
insertion	O
performance	O
,	O
aligning	O
with	O
findings	O
reported	O
in	O
prior	O
research	O
.	O

Goslin	B-BT
provides	O
information	O
on	O
the	O
hierarchical	O
level	O
of	O
the	O
lipids	O
in	O
the	O
data	O
set	O
.	O

From	O
the	O
mixture	O
data	O
set	O
,	O
seven	O
standard	O
metabolites	O
were	O
detected	O
by	O
the	O
four	O
quantitation	O
tools	O
,	O
for	O
which	O
iMet	B-BT
-	I-BT
Q	I-BT
had	O
a	O
smaller	O
quantitation	O
error	O
of	O
12	O
%	O
in	O
both	O
profile	O
and	O
centroid	O
data	O
sets	O
.	O

A	O
total	O
of	O
316	O
sequences	O
of	O
PSEN1	O
were	O
recovered	O
from	O
different	O
vertebrates	O
,	O
and	O
a	O
multiple	O
sequence	O
alignment	O
(	O
MSA	O
)	O
was	O
constructed	O
using	O
Jalview	B-BT
.	O

For	O
each	O
model	O
in	O
the	O
ensemble	O
,	O
enzyme	O
modules	O
were	O
constructed	O
for	O
each	O
reaction	O
using	O
a	O
nonlinear	O
parameter	O
fitting	O
package	O
(	O
https	O
://	O
github	O
.	O
com	O
/	O
opencobra	O
/	O
MASSef	B-BT
)	O
and	O
kinetic	O
data	O
extracted	O
from	O
the	O
literature	O
.	O

The	O
reported	O
value	O
of	O
average	O
(	O
AVG	O
),	O
standard	O
deviation	O
(	O
STD	O
),	O
median	O
(	O
MED	O
),	O
and	O
5th	O
and	O
95th	O
percentiles	O
refer	O
to	O
the	O
time	O
spent	O
annotating	O
15	O
documents	O
50	O
timesMA	O
+	O
CL	O
+	O
REAVGSTD5thMED95thOnlineMetaTron638	B-BT
.	O
731	O
.	O
67636	O
.	O
97638	O
.	O
22642	O
.	O
49TeamTat842	O
.	O
930	O
.	O
76841	O
.	O
67843	O
.	O
03844	O
.	O
18LightTag661	O
.	O
131	O
.	O
23659	O
.	O
35660	O
.	O
85663	O
.	O
07OfflineMetaTron642	B-BT
.	O
391	O
.	O
30640	O
.	O
35642	O
.	O
28644	O
.	O
54INCEpTION704	O
.	O
852	O
.	O
14701	O
.	O
53705	O
.	O
12707	O
.	O
33The	O
boldface	O
values	O
represent	O
avg	O
and	O
median	O
results	O
of	O
the	O
tools	O
with	O
the	O
best	O
performances	O
,	O
i	O
.	O
e	O
.,	O
the	O
lowest	O
time	O
taken	O
to	O
annotate	O
15	O
documents	O
50	O
times	O

Figure	O
1	O
shows	O
the	O
graphical	O
user	O
interface	O
of	O
RmsiGUI	B-BT
with	O
the	O
TrIQ	O
option	O
selector	O
.	O

The	O
surface	O
morphology	O
was	O
evaluated	O
using	O
TEM	O
(	O
JEM	O
-	O
2100F	O
,	O
JEOL	O
Ltd	O
.,	O
Tokyo	O
,	O
Japan	O
).	O

The	O
development	O
of	O
scAnnoX	B-BT
has	O
enabled	O
effective	O
analyses	O
of	O
single	O
-	O
cell	O
RNA	O
sequencing	O
data	O
,	O
streamlining	O
the	O
processes	O
of	O
testing	O
,	O
evaluating	O
,	O
and	O
comparing	O
multiple	O
algorithms	O
,	O
thereby	O
equipping	O
researchers	O
with	O
the	O
tools	O
necessary	O
to	O
navigate	O
the	O
complexity	O
of	O
algorithm	O
selection	O
.	O

The	O
peak	O
annotation	O
was	O
compared	O
by	O
calculating	O
the	O
fractions	O
of	O
false	O
positives	O
(	O
FP	O
),	O
false	O
negatives	O
(	O
FN	O
),	O
true	O
positives	O
(	O
TP	O
),	O
and	O
true	O
negatives	O
(	O
TN	O
)	O
of	O
all	O
observations	O
n	O
for	O
MZmine	B-BT
and	O
ATS	O
compared	O
to	O
the	O
manual	O
evaluation	O
in	O
TraceFinder	O
.	O

In	O
order	O
to	O
serve	O
the	O
scientific	O
community	O
,	O
we	O
have	O
also	O
developed	O
a	O
webserver	O
named	O
PhageTB	B-BT
and	O
provided	O
a	O
standalone	O
software	O
package	O
(	O
https	O
://	O
webs	O
.	O
iiitd	O
.	O
edu	O
.	O
in	O
/	O
raghava	O
/	O
phagetb	B-BT
/)	O
for	O
the	O
same	O
.	O

Although	O
there	O
are	O
some	O
outliers	O
with	O
a	O
high	O
reconstruction	O
error	O
,	O
SHAPRs	B-BT
was	O
generally	O
able	O
to	O
retrieve	O
real	O
-	O
world	O
3D	O
information	O
and	O
outperformed	O
naïve	O
3D	O
shape	O
fitting	O
models	O
on	O
both	O
datasets	O
.	O

Qualitative	O
interviews	O
were	O
conducted	O
to	O
assess	O
engagement	O
and	O
pain	O
points	O
with	O
the	O
InPACT	O
at	O
Home	O
website	O
.	O

Access	O
to	O
the	O
data	O
in	O
kmerDB	B-BT
is	O
facilitated	O
via	O
the	O
Browse	O
menu	O
located	O
at	O
the	O
kmerDB	B-BT
navigation	O
bar	O
.	O

If	O
there	O
is	O
a	O
demand	O
from	O
the	O
community	O
,	O
we	O
will	O
update	O
the	O
quickBAM	O
multiple	O
pileup	O
engine	O
to	O
behave	O
exactly	O
as	O
HTSLIB	B-BT
in	O
high	O
coverage	O
regions	O
.	O

KM	O
curves	O
of	O
groups	O
of	O
OS	O
from	O
OS	O
-	O
all	O
cohort	O
(	O
A	O
)	O
and	O
OS	O
-	O
slim	O
cohort	O
(	O
B	O
).	O

A	O
mixed	O
effects	O
model	O
with	O
repeated	O
measures	O
analysis	O
of	O
variance	O
was	O
used	O
to	O
compare	O
the	O
mean	O
of	O
each	O
expired	O
minute	O
ventilation	O
(	O
mL	O
/	O
min	O
),	O
volumetric	O
capnography	O
(	O
VCO2	O
[	O
mL	O
/	O
min	O
]),	O
and	O
PCaO2	O
between	O
PEEP	O
levels	O
assuming	O
an	O
autoregressive	O
order	O
[	O
AR	O
(	O
1	O
)]	O
correlation	O
structure	O
among	O
within	O
-	O
pig	O
repeated	O
measures	O
.	O

Only	O
MetaTron	B-BT
allows	O
the	O
user	O
to	O
specify	O
a	O
DOI	O
and	O
annotate	O
the	O
related	O
abstract	O
extracted	O
from	O
Semantic	O
Scholar	O
or	O
OpenAIRE	O
.	O

Finally	O
,	O
the	O
Marine	B-BT
Metagenomics	I-BT
Portal	I-BT
(	O
MMP	O
)	O
[	O
43	O
]	O
is	O
a	O
collection	O
of	O
databases	O
annotating	O
marine	O
-	O
oriented	O
metagenomic	O
datasets	O
,	O
retrieved	O
from	O
MGnify	O
as	O
well	O
as	O
super	O
studies	O
conducted	O
by	O
large	O
microbiome	O
initiatives	O
,	O
such	O
as	O
AtlantECO	O
or	O
the	O
Tara	O
Oceans	O
expedition	O
[	O
44	O
].	O

Table	O
1Characteristics	O
of	O
included	O
cancer	O
cases	O
across	O
different	O
treatment	O
phasesLung	O
cancerBreast	O
cancerColorectal	O
cancerEsophageal	O
cancerLiver	O
cancerGastric	O
cancerPhase	O
Ia	O
(	O
Surgical	O
-	O
related	O
treatment	O
),	O
N	O
*=	O
3738N	O
=	O
717N	O
=	O
824N	O
=	O
778N	O
=	O
376N	O
=	O
389N	O
=	O
654Region	O
,	O
N	O
(%)	O
North202	O
(	O
28	O
.	O
2	O
)	O
236	O
(	O
28	O
.	O
6	O
)	O
139	O
(	O
17	O
.	O
9	O
)	O
51	O
(	O
13	O
.	O
6	O
)	O
81	O
(	O
20	O
.	O
8	O
)	O
199	O
(	O
30	O
.	O
4	O
)	O
East182	O
(	O
25	O
.	O
4	O
)	O
193	O
(	O
23	O
.	O
4	O
)	O
213	O
(	O
27	O
.	O
4	O
)	O
140	O
(	O
37	O
.	O
2	O
)	O
92	O
(	O
23	O
.	O
7	O
)	O
148	O
(	O
22	O
.	O
6	O
)	O
Middle128	O
(	O
17	O
.	O
9	O
)	O
176	O
(	O
21	O
.	O
4	O
)	O
154	O
(	O
19	O
.	O
8	O
)	O
79	O
(	O
21	O
.	O
0	O
)	O
68	O
(	O
17	O
.	O
5	O
)	O
111	O
(	O
17	O
.	O
0	O
)	O
South88	O
(	O
12	O
.	O
3	O
)	O
80	O
(	O
9	O
.	O
7	O
)	O
91	O
(	O
11	O
.	O
7	O
)	O
35	O
(	O
9	O
.	O
3	O
)	O
64	O
(	O
16	O
.	O
5	O
)	O
67	O
(	O
10	O
.	O
2	O
)	O
West117	O
(	O
16	O
.	O
3	O
)	O
139	O
(	O
16	O
.	O
9	O
)	O
181	O
(	O
23	O
.	O
3	O
)	O
71	O
(	O
18	O
.	O
9	O
)	O
84	O
(	O
21	O
.	O
6	O
)	O
129	O
(	O
19	O
.	O
7	O
)	O
Hospital	O
type	O
,	O
N	O
(%)	O
General	O
hospital323	O
(	O
45	O
.	O
0	O
)	O
387	O
(	O
47	O
.	O
0	O
)	O
432	O
(	O
55	O
.	O
5	O
)	O
170	O
(	O
45	O
.	O
2	O
)	O
161	O
(	O
41	O
.	O
4	O
)	O
253	O
(	O
38	O
.	O
7	O
)	O
Specialized	O
hospital394	O
(	O
55	O
.	O
0	O
)	O
437	O
(	O
53	O
.	O
0	O
)	O
346	O
(	O
44	O
.	O
5	O
)	O
206	O
(	O
54	O
.	O
8	O
)	O
228	O
(	O
58	O
.	O
6	O
)	O
401	O
(	O
61	O
.	O
3	O
)	O
Age	O
at	O
diagnosis	O
Years	O
,	O
mean	O
(	O
SD	O
)	O
60	O
(	O
11	O
)	O
53	O
(	O
11	O
)	O
63	O
(	O
11	O
)	O
65	O
(	O
9	O
)	O
60	O
(	O
10	O
)	O
62	O
(	O
11	O
)	O
Gender	O
,	O
N	O
(%)	O
Male388	O
(	O
54	O
.	O
1	O
)	O
7	O
(	O
0	O
.	O
8	O
)	O
478	O
(	O
61	O
.	O
4	O
)	O
306	O
(	O
81	O
.	O
4	O
)	O
302	O
(	O
77	O
.	O
6	O
)	O
468	O
(	O
71	O
.	O
6	O
)	O
Female329	O
(	O
45	O
.	O
9	O
)	O
817	O
(	O
99	O
.	O
2	O
)	O
300	O
(	O
38	O
.	O
6	O
)	O
70	O
(	O
18	O
.	O
6	O
)	O
87	O
(	O
22	O
.	O
4	O
)	O
186	O
(	O
28	O
.	O
4	O
)	O
Clinical	O
stage	O
**,	O
N	O
(%)	O
I384	O
(	O
53	O
.	O
6	O
)	O
338	O
(	O
41	O
.	O
0	O
)	O
230	O
(	O
29	O
.	O
6	O
)	O
114	O
(	O
30	O
.	O
3	O
)	O
137	O
(	O
35	O
.	O
2	O
)	O
201	O
(	O
30	O
.	O
7	O
)	O
II151	O
(	O
21	O
.	O
1	O
)	O
281	O
(	O
34	O
.	O
1	O
)	O
210	O
(	O
27	O
.	O
0	O
)	O
114	O
(	O
30	O
.	O
3	O
)	O
111	O
(	O
28	O
.	O
5	O
)	O
159	O
(	O
24	O
.	O
3	O
)	O
III126	O
(	O
17	O
.	O
6	O
)	O
164	O
(	O
19	O
.	O
9	O
)	O
234	O
(	O
30	O
.	O
1	O
)	O
117	O
(	O
31	O
.	O
1	O
)	O
97	O
(	O
24	O
.	O
9	O
)	O
202	O
(	O
30	O
.	O
9	O
)	O
IV56	O
(	O
7	O
.	O
8	O
)	O
41	O
(	O
5	O
.	O
0	O
)	O
104	O
(	O
13	O
.	O
4	O
)	O
31	O
(	O
8	O
.	O
2	O
)	O
44	O
(	O
11	O
.	O
3	O
)	O
92	O
(	O
14	O
.	O
1	O
)	O
Phase	O
Ib	O
(	O
Non	O
-	O
surgical	O
treatment	O
),	O
N	O
=	O
5	O
,	O
940N	O
=	O
1	O
,	O
256N	O
=	O
1	O
,	O
282N	O
=	O
1	O
,	O
006N	O
=	O
719N	O
=	O
914N	O
=	O
763Region	O
,	O
N	O
(%)	O
North200	O
(	O
15	O
.	O
9	O
)	O
327	O
(	O
25	O
.	O
5	O
)	O
262	O
(	O
26	O
.	O
0	O
)	O
57	O
(	O
7	O
.	O
9	O
)	O
147	O
(	O
16	O
.	O
1	O
)	O
200	O
(	O
26	O
.	O
2	O
)	O
East307	O
(	O
24	O
.	O
4	O
)	O
224	O
(	O
17	O
.	O
5	O
)	O
194	O
(	O
19	O
.	O
3	O
)	O
251	O
(	O
34	O
.	O
9	O
)	O
221	O
(	O
24	O
.	O
2	O
)	O
213	O
(	O
27	O
.	O
9	O
)	O
Middle320	O
(	O
25	O
.	O
5	O
)	O
335	O
(	O
26	O
.	O
1	O
)	O
244	O
(	O
24	O
.	O
3	O
)	O
156	O
(	O
21	O
.	O
7	O
)	O
236	O
(	O
25	O
.	O
8	O
)	O
158	O
(	O
20	O
.	O
7	O
)	O
South126	O
(	O
10	O
.	O
0	O
)	O
191	O
(	O
14	O
.	O
9	O
)	O
141	O
(	O
14	O
.	O
0	O
)	O
91	O
(	O
12	O
.	O
7	O
)	O
158	O
(	O
17	O
.	O
3	O
)	O
79	O
(	O
10	O
.	O
4	O
)	O
West303	O
(	O
24	O
.	O
1	O
)	O
205	O
(	O
16	O
.	O
0	O
)	O
165	O
(	O
16	O
.	O
4	O
)	O
164	O
(	O
22	O
.	O
8	O
)	O
152	O
(	O
16	O
.	O
6	O
)	O
113	O
(	O
14	O
.	O
8	O
)	O
Hospital	O
type	O
,	O
N	O
(%)	O
General	O
hospital739	O
(	O
58	O
.	O
8	O
)	O
579	O
(	O
45	O
.	O
2	O
)	O
601	O
(	O
59	O
.	O
7	O
)	O
342	O
(	O
47	O
.	O
6	O
)	O
464	O
(	O
50	O
.	O
8	O
)	O
356	O
(	O
46	O
.	O
7	O
)	O
Specialized	O
hospital517	O
(	O
41	O
.	O
2	O
)	O
703	O
(	O
54	O
.	O
8	O
)	O
405	O
(	O
40	O
.	O
3	O
)	O
377	O
(	O
52	O
.	O
4	O
)	O
450	O
(	O
49	O
.	O
2	O
)	O
407	O
(	O
53	O
.	O
3	O
)	O
Age	O
at	O
diagnosis	O
Years	O
,	O
mean	O
(	O
SD	O
)	O
63	O
(	O
9	O
)	O
52	O
(	O
10	O
)	O
60	O
(	O
11	O
)	O
65	O
(	O
10	O
)	O
59	O
(	O
12	O
)	O
61	O
(	O
11	O
)	O
Gender	O
,	O
N	O
(%)	O
Male896	O
(	O
71	O
.	O
3	O
)	O
10	O
(	O
0	O
.	O
8	O
)	O
636	O
(	O
63	O
.	O
2	O
)	O
592	O
(	O
82	O
.	O
3	O
)	O
741	O
(	O
81	O
.	O
1	O
)	O
529	O
(	O
69	O
.	O
3	O
)	O
Female360	O
(	O
28	O
.	O
7	O
)	O
1	O
,	O
272	O
(	O
99	O
.	O
2	O
)	O
370	O
(	O
36	O
.	O
8	O
)	O
127	O
(	O
17	O
.	O
7	O
)	O
173	O
(	O
18	O
.	O
9	O
)	O
234	O
(	O
30	O
.	O
7	O
)	O
Clinical	O
stage	O
**,	O
N	O
(%)	O
I229	O
(	O
18	O
.	O
2	O
)	O
317	O
(	O
24	O
.	O
7	O
)	O
185	O
(	O
18	O
.	O
4	O
)	O
77	O
(	O
10	O
.	O
7	O
)	O
166	O
(	O
18	O
.	O
2	O
)	O
93	O
(	O
12	O
.	O
2	O
)	O
II205	O
(	O
16	O
.	O
3	O
)	O
429	O
(	O
33	O
.	O
5	O
)	O
271	O
(	O
26	O
.	O
9	O
)	O
178	O
(	O
24	O
.	O
8	O
)	O
228	O
(	O
24	O
.	O
9	O
)	O
194	O
(	O
25	O
.	O
4	O
)	O
III377	O
(	O
30	O
.	O
0	O
)	O
306	O
(	O
23	O
.	O
9	O
)	O
312	O
(	O
31	O
.	O
0	O
)	O
270	O
(	O
37	O
.	O
6	O
)	O
288	O
(	O
31	O
.	O
5	O
)	O
234	O
(	O
30	O
.	O
7	O
)	O
IV445	O
(	O
35	O
.	O
4	O
)	O
230	O
(	O
17	O
.	O
9	O
)	O
238	O
(	O
23	O
.	O
7	O
)	O
194	O
(	O
27	O
.	O
0	O
)	O
232	O
(	O
25	O
.	O
4	O
)	O
242	O
(	O
31	O
.	O
7	O
)	O
Phase	O
II	O
(	O
Follow	O
-	O
up	O
treatment	O
),	O
N	O
=	O
1	O
,	O
554N	O
=	O
283N	O
=	O
256N	O
=	O
262N	O
=	O
282N	O
=	O
201N	O
=	O
270Region	O
,	O
N	O
(%)	O
North26	O
(	O
9	O
.	O
2	O
)	O
43	O
(	O
16	O
.	O
8	O
)	O
12	O
(	O
4	O
.	O
6	O
)	O
15	O
(	O
5	O
.	O
3	O
)	O
6	O
(	O
3	O
.	O
0	O
)	O
32	O
(	O
11	O
.	O
9	O
)	O
East73	O
(	O
25	O
.	O
8	O
)	O
80	O
(	O
31	O
.	O
2	O
)	O
103	O
(	O
39	O
.	O
3	O
)	O
83	O
(	O
29	O
.	O
4	O
)	O
49	O
(	O
24	O
.	O
4	O
)	O
79	O
(	O
29	O
.	O
3	O
)	O
Middle67	O
(	O
23	O
.	O
7	O
)	O
37	O
(	O
14	O
.	O
5	O
)	O
69	O
(	O
26	O
.	O
3	O
)	O
49	O
(	O
17	O
.	O
4	O
)	O
30	O
(	O
14	O
.	O
9	O
)	O
32	O
(	O
11	O
.	O
9	O
)	O
South57	O
(	O
20	O
.	O
1	O
)	O
36	O
(	O
14	O
.	O
1	O
)	O
25	O
(	O
9	O
.	O
5	O
)	O
71	O
(	O
25	O
.	O
2	O
)	O
65	O
(	O
32	O
.	O
3	O
)	O
65	O
(	O
24	O
.	O
1	O
)	O
West60	O
(	O
21	O
.	O
2	O
)	O
60	O
(	O
23	O
.	O
4	O
)	O
53	O
(	O
20	O
.	O
2	O
)	O
64	O
(	O
22	O
.	O
7	O
)	O
51	O
(	O
25	O
.	O
4	O
)	O
62	O
(	O
23	O
.	O
0	O
)	O
Hospital	O
type	O
,	O
N	O
(%)	O
General	O
hospital124	O
(	O
43	O
.	O
8	O
)	O
109	O
(	O
42	O
.	O
6	O
)	O
159	O
(	O
60	O
.	O
7	O
)	O
124	O
(	O
44	O
.	O
0	O
)	O
56	O
(	O
27	O
.	O
9	O
)	O
107	O
(	O
39	O
.	O
6	O
)	O
Specialized	O
hospital159	O
(	O
56	O
.	O
2	O
)	O
147	O
(	O
57	O
.	O
4	O
)	O
103	O
(	O
39	O
.	O
3	O
)	O
158	O
(	O
56	O
.	O
0	O
)	O
145	O
(	O
72	O
.	O
1	O
)	O
163	O
(	O
60	O
.	O
4	O
)	O
Age	O
at	O
diagnosis	O
Years	O
,	O
mean	O
(	O
SD	O
)	O
61	O
(	O
11	O
)	O
53	O
(	O
11	O
)	O
62	O
(	O
11	O
)	O
64	O
(	O
9	O
)	O
60	O
(	O
12	O
)	O
61	O
(	O
11	O
)	O
Gender	O
,	O
N	O
(%)	O
Male173	O
(	O
61	O
.	O
1	O
)	O
3	O
(	O
1	O
.	O
2	O
)	O
161	O
(	O
61	O
.	O
5	O
)	O
233	O
(	O
82	O
.	O
6	O
)	O
169	O
(	O
84	O
.	O
1	O
)	O
173	O
(	O
64	O
.	O
1	O
)	O
Female110	O
(	O
38	O
.	O
9	O
)	O
253	O
(	O
98	O
.	O
8	O
)	O
101	O
(	O
38	O
.	O
5	O
)	O
49	O
(	O
17	O
.	O
4	O
)	O
32	O
(	O
15	O
.	O
9	O
)	O
97	O
(	O
35	O
.	O
9	O
)	O
Clinical	O
stage	O
**,	O
N	O
(%)	O
I100	O
(	O
35	O
.	O
3	O
)	O
67	O
(	O
26	O
.	O
2	O
)	O
52	O
(	O
19	O
.	O
8	O
)	O
66	O
(	O
23	O
.	O
4	O
)	O
62	O
(	O
30	O
.	O
8	O
)	O
65	O
(	O
24	O
.	O
1	O
)	O
II66	O
(	O
23	O
.	O
3	O
)	O
70	O
(	O
27	O
.	O
3	O
)	O
80	O
(	O
30	O
.	O
5	O
)	O
77	O
(	O
27	O
.	O
3	O
)	O
44	O
(	O
21	O
.	O
9	O
)	O
64	O
(	O
23	O
.	O
7	O
)	O
III62	O
(	O
21	O
.	O
9	O
)	O
55	O
(	O
21	O
.	O
5	O
)	O
96	O
(	O
36	O
.	O
6	O
)	O
81	O
(	O
28	O
.	O
7	O
)	O
55	O
(	O
27	O
.	O
4	O
)	O
63	O
(	O
23	O
.	O
3	O
)	O
IV55	O
(	O
19	O
.	O
4	O
)	O
64	O
(	O
25	O
.	O
0	O
)	O
34	O
(	O
13	O
.	O
0	O
)	O
58	O
(	O
20	O
.	O
6	O
)	O
40	O
(	O
19	O
.	O
9	O
)	O
78	O
(	O
28	O
.	O
9	O
)	O
Phase	O
III	O
(	O
Treatment	O
after	O
relapse	O
/	O
metastasis	O
),	O
N	O
=	O
2	O
,	O
513N	O
=	O
610N	O
=	O
446N	O
=	O
374N	O
=	O
329N	O
=	O
402N	O
=	O
352Region	O
,	O
N	O
(%)	O
North84	O
(	O
13	O
.	O
8	O
)	O
47	O
(	O
10	O
.	O
5	O
)	O
56	O
(	O
15	O
.	O
0	O
)	O
33	O
(	O
10	O
.	O
0	O
)	O
35	O
(	O
8	O
.	O
7	O
)	O
58	O
(	O
16	O
.	O
5	O
)	O
East148	O
(	O
24	O
.	O
3	O
)	O
111	O
(	O
24	O
.	O
9	O
)	O
102	O
(	O
27	O
.	O
3	O
)	O
78	O
(	O
23	O
.	O
7	O
)	O
102	O
(	O
25	O
.	O
4	O
)	O
129	O
(	O
36	O
.	O
6	O
)	O
Middle138	O
(	O
22	O
.	O
6	O
)	O
87	O
(	O
19	O
.	O
5	O
)	O
83	O
(	O
22	O
.	O
2	O
)	O
75	O
(	O
22	O
.	O
8	O
)	O
108	O
(	O
26	O
.	O
9	O
)	O
68	O
(	O
19	O
.	O
3	O
)	O
South67	O
(	O
11	O
.	O
0	O
)	O
103	O
(	O
23	O
.	O
1	O
)	O
53	O
(	O
14	O
.	O
2	O
)	O
54	O
(	O
16	O
.	O
4	O
)	O
72	O
(	O
17	O
.	O
9	O
)	O
49	O
(	O
13	O
.	O
9	O
)	O
West173	O
(	O
28	O
.	O
4	O
)	O
98	O
(	O
22	O
.	O
0	O
)	O
80	O
(	O
21	O
.	O
4	O
)	O
89	O
(	O
27	O
.	O
1	O
)	O
85	O
(	O
21	O
.	O
1	O
)	O
48	O
(	O
13	O
.	O
6	O
)	O
Hospital	O
type	O
,	O
N	O
(%)	O
General	O
hospital326	O
(	O
53	O
.	O
4	O
)	O
179	O
(	O
40	O
.	O
1	O
)	O
205	O
(	O
54	O
.	O
8	O
)	O
142	O
(	O
43	O
.	O
2	O
)	O
203	O
(	O
50	O
.	O
5	O
)	O
156	O
(	O
44	O
.	O
3	O
)	O
Specialized	O
hospital284	O
(	O
46	O
.	O
6	O
)	O
267	O
(	O
59	O
.	O
9	O
)	O
169	O
(	O
45	O
.	O
2	O
)	O
187	O
(	O
56	O
.	O
8	O
)	O
199	O
(	O
49	O
.	O
5	O
)	O
196	O
(	O
55	O
.	O
7	O
)	O
Age	O
at	O
diagnosis	O
Years	O
,	O
mean	O
(	O
SD	O
)	O
63	O
(	O
9	O
)	O
53	O
(	O
11	O
)	O
60	O
(	O
12	O
)	O
64	O
(	O
10	O
)	O
58	O
(	O
12	O
)	O
63	O
(	O
11	O
)	O
Gender	O
,	O
N	O
(%)	O
Male421	O
(	O
69	O
.	O
0	O
)	O
2	O
(	O
0	O
.	O
4	O
)	O
226	O
(	O
60	O
.	O
4	O
)	O
269	O
(	O
81	O
.	O
8	O
)	O
323	O
(	O
80	O
.	O
3	O
)	O
250	O
(	O
71	O
.	O
0	O
)	O
Female189	O
(	O
31	O
.	O
0	O
)	O
444	O
(	O
99	O
.	O
6	O
)	O
148	O
(	O
39	O
.	O
6	O
)	O
60	O
(	O
18	O
.	O
2	O
)	O
79	O
(	O
19	O
.	O
7	O
)	O
102	O
(	O
29	O
.	O
0	O
)	O
Clinical	O
stage	O
**,	O
N	O
(%)	O
I83	O
(	O
13	O
.	O
6	O
)	O
68	O
(	O
15	O
.	O
2	O
)	O
30	O
(	O
8	O
.	O
0	O
)	O
36	O
(	O
10	O
.	O
9	O
)	O
63	O
(	O
15	O
.	O
7	O
)	O
34	O
(	O
9	O
.	O
7	O
)	O
II62	O
(	O
10	O
.	O
2	O
)	O
98	O
(	O
22	O
.	O
0	O
)	O
53	O
(	O
14	O
.	O
2	O
)	O
54	O
(	O
16	O
.	O
4	O
)	O
66	O
(	O
16	O
.	O
4	O
)	O
51	O
(	O
14	O
.	O
5	O
)	O
III130	O
(	O
21	O
.	O
3	O
)	O
108	O
(	O
24	O
.	O
2	O
)	O
90	O
(	O
24	O
.	O
1	O
)	O
87	O
(	O
26	O
.	O
4	O
)	O
113	O
(	O
28	O
.	O
1	O
)	O
84	O
(	O
23	O
.	O
9	O
)	O
IV335	O
(	O
54	O
.	O
9	O
)	O
172	O
(	O
38	O
.	O
6	O
)	O
201	O
(	O
53	O
.	O
7	O
)	O
152	O
(	O
46	O
.	O
2	O
)	O
160	O
(	O
39	O
.	O
8	O
)	O
183	O
(	O
52	O
.	O
0	O
)	O
Note	O
*	O
N	O
stands	O
for	O
the	O
number	O
of	O
cases	O
counted	O
**	O
Clinical	O
stage	O
at	O
diagnosis	O

Critical	O
review	O
of	O
the	O
manuscript	O
for	O
important	O
intellectual	O
content	O
:	O
Kai	O
Yoshinaga	O
,	O
Artem	O
Tkachenko	O
,	O
Thomas	O
Murphy	O

Microvirus	O
host	O
taxonomy	O
to	O
the	O
genus	O
rank	O
was	O
predicted	O
using	O
iPHoP	B-BT
[	O
50	O
].	O

For	O
example	O
,	O
[	O
29	O
]	O
modifies	O
cooltools	B-BT
to	O
extract	O
50	O
+	O
eigenvectors	O
,	O
which	O
are	O
then	O
used	O
to	O
find	O
multiple	O
classes	O
of	O
compartments	O
.	O

We	O
resampled	O
the	O
FRET	O
efficiency	O
1000	O
times	O
,	O
computed	O
using	O
FRETpredict45	B-BT
with	O
repetition	O
,	O
and	O
calculated	O
the	O
mean	O
of	O
each	O
sample	O
.	O

Clicking	O
the	O
‘	O
Run	O
’	O
button	O
runs	O
the	O
RNAscape	B-BT
pipeline	O
on	O
the	O
uploaded	O
structure	O
file	O
or	O
provided	O
PDB	O
ID	O
(	O
biological	O
assembly	O
1	O
).	O

Note	O
that	O
Fiji	B-BT
needs	O
to	O
be	O
restarted	O
for	O
the	O
changes	O
to	O
take	O
effect	O
.	O

RNA	O
-	O
seq	O
data	O
processing	O
,	O
including	O
quality	O
control	O
,	O
read	O
trimming	O
,	O
alignment	O
,	O
and	O
expression	O
quantification	O
by	O
read	O
counting	O
,	O
was	O
carried	O
out	O
as	O
described	O
previously	O
47	O
,	O
using	O
our	O
standard	O
clinical	O
RNA	O
-	O
seq	O
pipeline	O
‘‘	O
CRISP	O
’’	O
(	O
available	O
at	O
https	O
://	O
github	O
.	O
com	O
/	O
mcieslik	O
-	O
mctp	O
/	O
bootstrap	O
-	O
rnascape	B-BT
).	O

As	O
insider	O
researchers	O
,	O
we	O
have	O
a	O
duty	O
to	O
prioritize	O
research	O
questions	O
that	O
reflect	O
the	O
full	O
spectrum	O
of	O
lived	O
experiences	O
.	O

We	O
believe	O
that	O
PhageTB	B-BT
will	O
be	O
an	O
effective	O
method	O
for	O
prediction	O
of	O
phage	O
-	O
based	O
therapy	O
against	O
bacterial	O
infections	O
.	O

In	O
the	O
new	O
cost	O
matrix	O
calculation	O
method	O
,	O
we	O
use	O
weighted	O
FCs	O
as	O
the	O
feature	O
to	O
calculate	O
the	O
distance	O
between	O
CT	O
and	O
spots	O
and	O
then	O
optimize	O
the	O
baseline	O
mapping	O
matrix	O
(	O
e	O
.	O
g	O
.,	O
TACCO	B-BT
output	O
).	O

We	O
thank	O
the	O
Cyprus	O
Institute	O
of	O
Neurology	O
and	O
Genetics	O
for	O
computer	O
equipment	O
and	O
for	O
hosting	O
ITHANET	B-BT
.	O

The	O
data	O
transfer	O
time	O
—	O
from	O
OncoPanel	O
sign	O
-	O
out	O
to	O
when	O
the	O
data	O
are	O
ingested	O
into	O
MatchMiner	B-BT
and	O
algorithmically	O
matched	O
—	O
is	O
1	O
-	O
2	O
days	O
.	O

Here	O
we	O
report	O
antegrade	O
metallic	O
stenting	O
using	O
a	O
slim	O
cholangioscope	O
for	O
malignant	O
afferent	O
loop	O
obstruction	O
(	O
Video	O
1	O
).	O

A	O
possible	O
drawback	O
of	O
the	O
runtime	O
compilation	O
stems	O
from	O
the	O
relative	O
slowness	O
of	O
the	O
compiler	O
—	O
for	O
small	O
models	O
,	O
the	O
total	O
execution	O
time	O
of	O
MaBoSS	B-BT
.	O
GPU	O
may	O
be	O
easily	O
dominated	O
by	O
the	O
compilation	O
.	O

Bcftools	B-BT
did	O
not	O
detect	O
any	O
variants	O
at	O
allele	O
frequencies	O
<	O
∼	O
0	O
.	O
08	O
in	O
any	O
of	O
the	O
spiked	O
-	O
in	O
datasets	O
.	O

Given	O
that	O
mesocosms	O
are	O
intrinsically	O
warmer	O
than	O
outside	O
,	O
present	O
‐	O
day	O
climates	O
matched	O
thermal	O
conditions	O
near	O
the	O
Metatron	O
(	O
meteorological	O
station	O
of	O
Saint	O
‐	O
Girons	O
Antichan	O
;	O
Bestion	O
,	O
Teyssier	O
,	O
et	O
al	O
.,	O
2015	O
).	O

Admix	B-BT
-	I-BT
kit	I-BT
package	O
is	O
open	O
-	O
source	O
and	O
available	O
at	O
https	O
://	O
github	O
.	O
com	O
/	O
KangchengHou	O
/	O
admix	B-BT
-	I-BT
kit	I-BT
.	O

By	O
observing	O
the	O
EWL	O
structure	O
,	O
extracting	O
EMAA	O
and	O
the	O
fiber	O
bundles	O
and	O
matrix	O
influenced	O
by	O
EMAA	O
(	O
stitch	O
-	O
influenced	O
area	O
),	O
a	O
local	O
mesoscopic	O
RVE	O
model	O
was	O
constructed	O
,	O
as	O
shown	O
in	O
Figure	O
4a	O
,	O
where	O
the	O
fibers	O
in	O
the	O
X	O
and	O
Y	O
directions	O
represent	O
the	O
warp	O
and	O
weft	O
fibers	O
,	O
respectively	O
.	O

The	O
cumulative	O
distributions	O
of	O
error	O
across	O
all	O
identified	O
IPA	O
sites	O
were	O
compared	O
between	O
InPACT	B-BT
and	O
IPAFinder	O
.	O

In	O
this	O
issue	O
,	O
we	O
delve	O
into	O
early	O
childhood	O
education	O
in	O
Delaware	O
,	O
with	O
articles	O
curated	O
by	O
our	O
esteemed	O
guest	O
editors	O
Madeleine	O
Bayard	O
,	O
Senior	O
Vice	O
President	O
at	O
Rodel	O
,	O
and	O
Matt	O
Amis	O
,	O
Director	O
of	O
Communications	O
.	O

OralExplorer	B-BT
consists	O
of	O
5	O
main	O
analysis	O
modules	O
(	O
differential	O
gene	O
expression	O
analysis	O
,	O
immune	O
infiltration	O
analysis	O
,	O
correlation	O
analysis	O
,	O
pathway	O
enrichment	O
analysis	O
and	O
single	O
-	O
cell	O
analysis	O
),	O
with	O
multiple	O
visualization	O
options	O
.	O

Given	O
the	O
difference	O
in	O
the	O
five	O
subcellular	O
locations	O
covered	O
by	O
the	O
DM3Loc	O
,	O
MRSLpred	B-BT
,	O
and	O
Wang	O
et	O
al	O
.’	O
s	O
predictors	O
in	O
the	O
experiments	O
,	O
DRpred	O
is	O
separately	O
compared	O
with	O
these	O
predictors	O
.	O

Costs	O
obtained	O
in	O
other	O
years	O
and	O
/	O
or	O
different	O
currencies	O
converted	O
to	O
Fijian	O
dollar	O
using	O
the	O
average	O
exchange	O
rate	O
in	O
that	O
year	O
[	O
21	O
],	O
adjusted	O
to	O
2020	O
prices	O
using	O
GDP	O
deflator	O
[	O
22	O
],	O
and	O
converted	O
back	O
to	O
US	O
$	O
using	O
2020	O
exchange	O
rates	O
.	O

2	O
https	O
://	O
jubrain	O
.	O
fz	O
-	O
juelich	O
.	O
de	O
/	O
apps	O
/	O
cytoviewer2	B-BT
/	O
cytoviewer	B-BT
-	I-BT
main	O
.	O
php	O

With	O
the	O
isotope	O
ratios	O
calculated	O
by	O
iMet	B-BT
-	I-BT
Q	I-BT
,	O
49	O
%	O
(	O
89	O
out	O
of	O
183	O
)	O
metabolite	O
candidates	O
were	O
filtered	O
out	O
.	O

a	O
The	O
top	O
L	O
precisions	O
of	O
DeepTMP	O
,	O
CDPred	B-BT
,	O
DeepHomo2	O
.	O
0	O
,	O
GLINTER	O
,	O
DeepHomo	O
,	O
and	O
DNCON2_Inter	O
in	O
different	O
ranges	O
of	O
contact	O
density	O
.	O

The	O
unsupervised	O
version	O
of	O
scDREAMER	B-BT
employs	O
an	O
adversarial	O
variational	O
autoencoder	O
and	O
a	O
batch	O
classifier	O
(	O
a	O
multi	O
-	O
layer	O
neural	O
network	O
)	O
which	O
are	O
trained	O
adversarially	O
for	O
learning	O
batch	O
-	O
invariant	O
lower	O
-	O
dimensional	O
cellular	O
embeddings	O
.	O

Making	O
the	O
macros	O
available	O
from	O
a	O
Fiji	B-BT
menu	O
.	O

By	O
providing	O
these	O
analytical	O
tools	O
,	O
SpatialCells	B-BT
empowers	O
researchers	O
to	O
gain	O
deeper	O
insights	O
into	O
the	O
intricate	O
spatial	O
relationships	O
and	O
characteristics	O
of	O
cells	O
within	O
the	O
TME	O
.	O

As	O
can	O
be	O
seen	O
in	O
Figure	O
4	O
and	O
detailed	O
in	O
Supplementary	O
Table	O
S5	O
,	O
Enhancer	B-BT
-	I-BT
MDLF	I-BT
consistently	O
outperforms	O
Enhancer	O
-	O
IF	O
across	O
all	O
five	O
metrics	O
and	O
all	O
cell	O
lines	O
,	O
demonstrating	O
its	O
significant	O
superiority	O
.	O

To	O
avoid	O
large	O
RAM	O
consumption	O
,	O
we	O
implemented	O
the	O
greedy	O
algorithm	O
for	O
tab	O
-	O
separated	O
merging	O
and	O
incremental	O
PCA	O
plot	O
limiter	O
from	O
MerCat2	B-BT
(	O
Figueroa	O
III	O
et	O
al	O
.	O

The	O
social	O
sciences	O
use	O
the	O
term	O
‘	O
insider	O
’	O
(	O
vs	O
‘	O
outsider	O
’)	O
to	O
describe	O
when	O
the	O
researcher	O
belongs	O
to	O
the	O
group	O
they	O
are	O
studying	O
based	O
on	O
a	O
shared	O
ethnicity	O
,	O
sexual	O
identity	O
and	O
gender	O
.	O
2	O
,	O
6	O
,	O
23	O
–	O
25	O
It	O
can	O
also	O
be	O
used	O
to	O
describe	O
when	O
the	O
researcher	O
shares	O
with	O
study	O
participants	O
some	O
lived	O
experience	O
.	O
7	O
,	O
26	O
–	O
29	O
Insider	O
-	O
outsider	O
status	O
is	O
not	O
dichotomous	O
as	O
there	O
is	O
a	O
diversity	O
of	O
experiences	O
among	O
‘	O
insiders	O
’,	O
and	O
each	O
person	O
has	O
multiple	O
social	O
identities	O
;	O
insider	O
status	O
may	O
also	O
change	O
over	O
time	O
.	O
23	O
Research	O
by	O
a	O
‘	O
person	O
with	O
lived	O
experience	O
’	O
has	O
distinct	O
challenges	O
and	O
benefits	O
.	O

Applied	O
on	O
the	O
SNP	O
groups	O
aggregated	O
from	O
co	O
-	O
expression	O
gene	O
modules	O
,	O
BayesKAT	B-BT
is	O
able	O
to	O
pinpoint	O
specific	O
modules	O
as	O
significantly	O
associated	O
with	O
the	O
whole	O
brain	O
volume	O
trait	O
(	O
Figure	O
6B	O
Left	O
).	O

Therefore	O
,	O
the	O
ACE	O
-	O
I	O
-	O
ALG	O
-	O
CS	O
NPs	O
prepared	O
via	O
ionic	O
gelation	O
and	O
polyelectrolyte	O
complexation	O
demonstrate	O
capability	O
as	O
successful	O
nanocarriers	O
for	O
improving	O
the	O
physicochemical	O
stability	O
,	O
bioavailability	O
,	O
and	O
in	O
vivo	O
efficacy	O
of	O
food	O
-	O
derived	O
peptides	O
,	O
facilitating	O
their	O
incorporation	O
as	O
therapeutic	O
ingredients	O
into	O
functional	O
food	O
formulations	O
.	O

An	O
important	O
feature	O
of	O
KGD	O
is	O
that	O
four	O
modules	O
recently	O
developed	O
by	O
our	O
groups	O
,	O
a	O
‘	O
GO	O
tool	O
’,	O
‘	O
Pathway	O
tool	O
’,	O
‘	O
SyntenyViewer	B-BT
’	O
and	O
‘	O
RNA	O
-	O
Seq	O
’,	O
have	O
been	O
implemented	O
to	O
extend	O
the	O
capabilities	O
of	O
the	O
database	O
.	O

We	O
thank	O
the	O
youth	O
group	O
of	O
specialty	O
committee	O
of	O
network	O
pharmacology	O
of	O
World	O
Federation	O
of	O
Chinese	O
Medicine	O
Societies	O
(	O
WFCMS	O
)	O
for	O
their	O
helpful	O
comments	O
and	O
suggestions	O
,	O
which	O
substantially	O
improved	O
the	O
design	O
of	O
TCMNPAS	B-BT
.	O

PyCoMo	B-BT
could	O
detect	O
a	O
thermodynamically	O
infeasible	O
cycle	O
as	O
the	O
reason	O
,	O
allowing	O
D	O
.	O
vulgaris	O
to	O
take	O
up	O
H2	O
(	O
see	O
Supplementary	O
Material	O
,	O
Section	O
3	O
).	O

Therefore	O
,	O
we	O
primarily	O
focused	O
on	O
comparing	O
InPACT	B-BT
with	O
APAIQ	O
and	O
IPAFinder	O
by	O
evaluating	O
various	O
aspects	O
of	O
performance	O
.	O

DAA	O
should	O
be	O
suspected	O
when	O
airway	O
symptoms	O
are	O
already	O
present	O
in	O
early	O
infancy	O
,	O
particularly	O
if	O
a	O
right	O
aortic	O
arch	O
is	O
noted	O
.	O

All	O
data	O
in	O
CovEpiAb	B-BT
are	O
available	O
at	O
https	O
://	O
pgx	O
.	O
zju	O
.	O
edu	O
.	O
cn	O
/	O
covepiab	B-BT
.	O

We	O
train	O
the	O
machine	O
learning	O
methods	O
on	O
different	O
training	O
datasets	O
(	O
i	O
.	O
e	O
.,	O
Platinum	O
(	O
no	O
tyrosine	O
kinase	O
),	O
Platinum	O
,	O
and	O
MdrDB_Coreset	B-BT
(	O
single	O
substitution	O
))	O
and	O
report	O
the	O
test	O
performance	O
averaged	O
over	O
five	O
repetitions	O
for	O
each	O
method	O
on	O
the	O
TKI	O
dataset	O
in	O
Fig	O
.	O

We	O
also	O
determined	O
ACE	O
levels	O
in	O
blood	O
samples	O
obtained	O
from	O
newborns	O
(	O
twenty	O
-	O
four	O
carriers	O
of	O
eight	O
different	O
ACE	O
mutations	O
and	O
fifteen	O
controls	O
)	O
using	O
only	O
one	O
mAb	O
9B9	O
due	O
to	O
the	O
very	O
limited	O
volume	O
of	O
these	O
plasma	O
samples	O
.	O

Panels	O
A	O
and	O
B	O
(	O
x100	O
objective	O
):	O
Plasma	O
cells	O
with	O
numerous	O
large	O
cytoplasmic	O
granules	O
and	O
a	O
few	O
Snapper	O
‐	O
Schneid	O
bodies	O
(	O
arrows	O
).	O

(	O
Step	O
3	O
)	O
Function	O
‘	O
Contextualize	O
with	O
Flux	O
Data	O
’:	O
Visualization	O
of	O
flux	O
ranges	O
of	O
potential	O
exchange	O
reactions	O
,	O
independent	O
of	O
the	O
community	O
composition	O
and	O
calculated	O
with	O
PyCoMo	B-BT
.	O

With	O
three	O
modes	O
of	O
use	O
,	O
MatchMiner	B-BT
can	O
be	O
used	O
to	O
look	O
up	O
trials	O
for	O
individual	O
patients	O
or	O
to	O
recruit	O
patients	O
for	O
a	O
trial	O
.	O

While	O
SIRIUS	B-BT
correctly	O
assigned	O
the	O
chemical	O
formula	O
C15H24O2	O
,	O
the	O
cosine	O
similarity	O
between	O
SIRIUS	B-BT
predicted	O
fingerprint	O
and	O
correct	O
structure	O
fingerprint	O
was	O
only	O
0	O
.	O
33	O
,	O
indicating	O
that	O
MS2	O
data	O
were	O
insufficient	O
for	O
correct	O
fingerprint	O
prediction	O
.	O

Here	O
,	O
we	O
describe	O
cytoviewer	B-BT
,	O
an	O
R	O
/	O
Bioconductor	O
package	O
for	O
interactive	O
visualization	O
and	O
exploration	O
of	O
multi	O
-	O
channel	O
images	O
and	O
segmentation	O
masks	O
.	O

Smith	O
(	O
past	O
PI	O
);	O
Univ	O
of	O
Massachusetts	O
(	O
4	O
)	O
-	O
Ajit	O
Puri	O
(	O
PI	O
),	O
Francesco	O
Massari	O
(	O
Sub	O
-	O
I	O
),	O
Mary	O
Howk	O
(	O
CRC	O
),	O
David	O
Rex	O
(	O
past	O
Sub	O
-	O
I	O
),	O
Kimberly	O
Ty	O
(	O
past	O
CRC	O
),	O
Jen	O
Donham	O
(	O
past	O
CRC	O
),	O
Wen	O
Li	O
(	O
past	O
CRC	O
);	O
University	O
of	O
Kentucky	O
(	O
4	O
)	O
-	O
Justin	O
Fraser	O
(	O
current	O
PI	O
and	O
past	O
Sub	O
-	O
I	O
),	O
Stephen	O
Grupke	O
(	O
Sub	O
-	O
I	O
),	O
Jennifer	O
Isaacs	O
(	O
CRC	O
),	O
Abdulnasser	O
Alhajeri	O
(	O
past	O
PI	O
),	O
Caroline	O
Rodgers	O
(	O
past	O
CRC	O
);	O
Linda	O
Joyce	O
McCown	O
(	O
past	O
CRC	O
);	O
Houston	O
Methodist	O
Hospital	O
(	O
4	O
)	O
-	O
Richard	O
Klucznik	O
(	O
PI	O
),	O
Orlando	O
Diaz	O
(	O
Sub	O
-	O
I	O
),	O
Gavin	O
Britz	O
(	O
Sub	O
-	O
I	O
),	O
Yi	O
Zhang	O
(	O
Sub	O
-	O
I	O
),	O
Michelle	O
Prystash	O
(	O
CRC	O
),	O
Vivian	O
Escamilla	O
(	O
CRC	O
),	O
Adrienne	O
New	O
(	O
CRC	O
),	O
Liliana	O
Calderon	O
(	O
past	O
CRC	O
),	O
Elmira	O
Ramos	O
(	O
past	O
CRC	O
),	O
Ramon	O
Guardiola	O
(	O
past	O
CRC	O
),	O
Bhavin	O
Shah	O
(	O
past	O
CRC	O
),	O
Lenis	O
Sosa	O
(	O
past	O
CRC	O
),	O
Melissa	O
Whipple	O
(	O
past	O
CRC	O
);	O
Medical	O
University	O
of	O
South	O
Carolina	O
(	O
4	O
)	O
-	O
Alejandro	O
Spiotta	O
(	O
current	O
PI	O
and	O
past	O
Sub	O
-	O
I	O
),	O
Jonathan	O
Lena	O
(	O
Sub	O
-	O
I	O
),	O
Ayesha	O
Vohra	O
(	O
CRC	O
),	O
Meredith	O
Robinson	O
(	O
CRC	O
),	O
Aquilla	O
Turk	O
(	O
past	O
PI	O
),	O
Mohamad	O
Chaudry	O
(	O
past	O
Sub	O
-	O
I	O
),	O
Kyle	O
Fargen	O
(	O
past	O
Sub	O
-	O
I	O
),	O
Raymond	O
Turner	O
(	O
past	O
Sub	O
-	O
I	O
),	O
Emily	O
Young	O
(	O
past	O
CRC	O
),	O
Adrian	O
Parker	O
(	O
past	O
CRC	O
),	O
Angela	O
Robinson	O
(	O
past	O
CRC	O
),	O
Andrew	O
Dippre	O
(	O
past	O
CRC	O
),	O
Anita	O
Deveaux	O
(	O
past	O
CRC	O
),	O
Amora	O
Mayo	O
-	O
Perez	O
(	O
past	O
CRC	O
);	O
Baylor	O
College	O
of	O
Medicine	O
(	O
3	O
)	O
-	O
Peter	O
Kan	O
(	O
PI	O
),	O
Bridget	O
Solis	O
(	O
CRC	O
),	O
Melyssa	O
Fink	O
(	O
CRC	O
),	O
Edward	O
Duckworth	O
(	O
past	O
Sub	O
-	O
I	O
),	O
Samantha	O
Macias	O
(	O
CRC	O
),	O
Gilberto	O
DeFreitas	O
(	O
CRC	O
),	O
Stephen	O
Harold	O
(	O
CRC	O
),	O
Sree	O
Vidya	O
(	O
past	O
CRC	O
);	O
Los	O
Robles	O
Regional	O
(	O
3	O
)	O
-	O
Muhammad	O
Asif	O
Taqi	O
(	O
PI	O
),	O
Anastasia	O
Vechera	O
(	O
CRC	O
),	O
Samuel	O
Hou	O
(	O
past	O
Sub	O
-	O
I	O
),	O
Sajid	O
Suriya	O
(	O
past	O
CRC	O
),	O
Syed	O
Quadri	O
(	O
past	O
CRC	O
);	O
Methodist	O
Healthcare	O
Memphis	O
(	O
2	O
)	O
-	O
Adam	O
S	O
Arthur	O
(	O
PI	O
),	O
Lucas	O
Elijovich	O
(	O
Sub	O
-	O
I	O
),	O
Daniel	O
Hoit	O
(	O
Sub	O
-	O
I	O
),	O
Christopher	O
Nickele	O
(	O
Sub	O
-	O
I	O
),	O
Amanda	O
Nolte	O
(	O
CRC	O
),	O
Jessica	O
Jameson	O
(	O
CRC	O
),	O
Barrett	O
Patel	O
(	O
CRC	O
),	O
Hani	O
Rashed	O
(	O
CRC	O
),	O
Jay	O
Vachhani	O
(	O
past	O
Sub	O
-	O
I	O
),	O
Vinodh	O
Thomas	O
Doss	O
(	O
past	O
Sub	O
-	O
I	O
);	O
Rush	O
University	O
(	O
2	O
)	O
-	O
Richard	O
W	O
Crowley	O
(	O
current	O
PI	O
and	O
past	O
Sub	O
-	O
I	O
),	O
Bartosz	O
Jacher	O
(	O
CRC	O
),	O
Demetrius	O
Lopes	O
(	O
past	O
PI	O
),	O
Carol	O
Macpherson	O
(	O
past	O
CRC	O
),	O
Amanda	O
Arand	O
(	O
past	O
CRC	O
),	O
Christy	O
Anton	O
(	O
past	O
CRC	O
),	O
Michael	O
Chen	O
(	O
past	O
Sub	O
-	O
I	O
),	O
John	O
Dao	O
(	O
past	O
CRC	O
),	O
Francisco	O
Acosta	O
(	O
past	O
CRC	O
);	O
Harborview	O
Medical	O
Center	O
(	O
2	O
)	O
-	O
Danial	O
Hallam	O
(	O
PI	O
),	O
Basavaraj	O
Ghodke	O
(	O
Sub	O
-	O
I	O
),	O
Michael	O
Levitt	O
(	O
Sub	O
-	O
I	O
),	O
Kellie	O
Sheehan	O
(	O
CRC	O
),	O
Louis	O
Kim	O
(	O
Sub	O
-	O
I	O
);	O
SSM	O
DePaul	O
Health	O
Center	O
(	O
2	O
)	O
-	O
Richard	O
Callison	O
(	O
PI	O
),	O
Amer	O
Alshekhlee	O
(	O
Sub	O
-	O
I	O
),	O
Michelle	O
Raymond	O
(	O
CRC	O
),	O
Sushant	O
Kale	O
(	O
past	O
Sub	O
-	O
I	O
);	O
Vanderbilt	O
University	O
(	O
1	O
)	O
-	O
Michael	O
Froehler	O
(	O
PI	O
),	O
Matt	O
Fusco	O
(	O
Sub	O
-	O
I	O
),	O
Rohan	O
Chitale	O
(	O
Sub	O
-	O
I	O
),	O
Drew	O
Anderson	O
(	O
CRC	O
),	O
Natalie	O
Hall	O
(	O
CRC	O
),	O
Sally	O
(	O
Sarah	O
)	O
Baggette	O
(	O
CRC	O
),	O
Dima	O
Sbenaty	O
(	O
past	O
CRC	O
),	O
Kathryn	O
McNabb	O
(	O
past	O
CRC	O
),	O
Morgan	O
A	O
Pittman	O
(	O
past	O
CRC	O
),	O
Joy	O
Grabenstein	O
(	O
past	O
CRC	O
),	O
David	O
McKeel	O
(	O
past	O
CRC	O
).	O

Guguchkin	O
Egor	O
,	O
Kasianov	O
Artem	O
,	O
Belenikin	O
Maksim	O
,	O
Zobkova	O
Gaukhar	O
,	O
Kosova	O
Ekaterina	O
,	O
Makeev	O
Vsevolod	O
and	O
Karpulevich	O
Evgeny	O

